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Abstract
Distance Measures in Bioinformatics
Feiyu Xiong
Advisor: Drs. Moshe Kam and Leonid Hrebien, Ph.D.
Many bioinformatics applications rely on the computation of similarities between
objects. Distance and similarity measures applied to vectors of characteristics are
essential to problems such as classification, clustering and information retrieval.
This study explores the usefulness of distance and similarity measures in several
bioinformatics applications. These applications are in two categories.
(1) Estimation of the adverse reaction severity of unknown pharmaceutical treat-
ments, based on the severity of known treatments, in order to provide guidance for
testing of the unknown treatments in clinical trials.
(2) Classification of cancer tissue types and estimation of cancer stages, based on
high-dimensional microarray data, in order to support clinical decisions making.
To address the first category, we studied several clustering and classification ap-
proaches for binary severity estimation of Cytokine Release Syndrome (CRS). We
developed a Severity Estimation using Distance Metric Learning (SE-DML) approach
to get graded severity estimation. With binary estimation we were able to identify
treatments that caused the most severe response and then built prediction models for
CRS. Using the SE-DML approach, we evaluated four known data sets and showed
that SE-DML outperformed other widely used methods on these data sets.
For the second category, we presented Kernelized Information-Theoretic Metric
Learning (KITML) algorithms that optimize distance metrics and effectively handle
high-dimensional data. This learned metric by KITML is used to improve the per-
formance of k-nearest neighbor classification for cancer tissue microarray data. We
xevaluated our approach on fourteen (14) cancer microarray data sets and compared
our results with other state-of-the-art approaches. We achieved the best overall per-
formance for the classification task. In addition we tested the KITML algorithm in
estimating the severity stages of cancer samples, with accurate results.

11. Introduction
1.1 Motivation and Overview
Machine learning tasks involve the comparison of data samples in term of some
distance/similarity measures. These measures are essential to classification, clustering
and information retrieval tasks [4]. In bioinformatics, the concept of similarity is
fundamental to the study of macromolecular structures, genomes, proteomes and
metabolic pathways. For example, to determine whether a test treatment will have
similar adverse reaction as a known treatment, it is common to measure the similarity
between vectors of characteristics of samples of both treatments.
Let X be a set of data points. A distance/similarity measure on X is a function
d : X×X→ R. For all x, y, z in X, this function is required to satisfy the following
conditions [5]:
• d(x, y) ≥ 0 (non-negativity)
• d(x, y) = 0, if and only if x = y (coincidence)
• d(x, y) = d(y, x) (symmetry)
• d(x, z) ≤ d(x, y) + d(y, z) (triangle inequality).
There are many distance/similarity measures in use, including the Euclidean dis-
tance, Mahalanobis distance and Pearson correlation. How to choose and use these
measures is important in practical applications. For example, studies show that
simple nearest neighbor methods work if an appropriate distance measure is cho-
sen [6, 7, 8, 9]. Clustering algorithms such as K-means clustering also rely on the
pairwise distance measurements between samples [10] and the right choice of metric
makes significant difference in the accuracy of the analyses.
2In this study, we develop distance/similarity measures to address two kinds of
problems. The first problem type is severity estimation, the estimation of disease
states or adverse-reactions to a treatment (drug, regiment, behavior modification,
etc.). There are many reasons to study severity estimation including the need to
understand the stage of a condition/disease; to match a treatment to the severity at
which a condition is manifested; and to track the progression of a condition/disease.
Although researchers have developed diagnostic scores for predicting disease states
and clinical outcomes [11, 12], the process of determining the scores is time consum-
ing and expensive [13, 14]. To address this issue, we first perform binary severity
estimation, e.g., determining whether or not a treatment will have a similar adverse-
reaction severity to that of a known treatment. Next we apply a Severity Estimation
using Distance Metric Learning approach (SE-DML). This is a generalized approach
that provides quantitative severity determination that is applicable for several areas
in bioinformatics. Our binary severity estimation is evaluated on Cytokine Release
Syndrome (CRS) data. The SE-DML approach is evaluated on several data sets,
including CRS data, Cardiotocography (CTG) data, and two Quantitative Structure
Activity Relationship (QSAR) data sets.
The second problem we studied is cancer tissue classification using high-dimensional
molecular profiling data. Recent advances in molecular profiling technologies have en-
abled researchers to query the expression values of thousands of genes simultaneously.
Information derived from such genome-wide molecular profiling is important in the
diagnosis and identification of cancer tissue types in patient samples [15, 16]. An im-
portant emerging medical application domain for microarray technologies is clinical
decision support in the form of diagnosis of disease as well as the prediction of clinical
outcomes in response to treatments [16]. When mining molecular signature data, the
process of comparing samples through an adaptive distance function is fundamental
3but difficult, as such data sets are normally heterogeneous and high dimensional. In
this thesis, we present Kernelized Information-Theoretic Metric Learning (KITML)
algorithms that optimize a distance function to tackle the cancer tissue classifica-
tion problem. We study two applications of KITML using high-dimensional cancer
molecular profiling data. (1) for sample-level cancer tissue classification, the learned
metric is used to improve the performance of k-nearest neighbor classification. (2) for
estimating the severity level or stage of a group of samples, we propose a set-based
ranking approach to extend KITML.
1.2 Cytokine Release Syndrome (CRS)
1.2.1 Overview
Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor
therapy, but can cause a variety of adverse side effects [17]. One of these is Cytokine
Release Syndrome (CRS), which is characterized by the systemic release of several
inflammatory mediators which set off a cascade release of cytokines [18]. Symptoms
of CRS can include fatigue, headache, urticaria, pruritus, bronchospasm, dyspnea,
sensation of tongue or throat swelling, rhinitis, nausea, vomiting, flushing, fever,
chills, hypotension, tachycardia and asthenia [19]. Some CRS reactions are mild to
moderate in severity and can be controlled by slowing the infusion rate of the mAb
or by administering anti-inflammatory drugs [18]. However in a 2006 phase I clinical
trial using Anti-CD28 SA mAb (TGN 1412), the reactions were much more severe
and six healthy volunteers developed severe CRS within 90 minutes of receiving a
dose of Anti-CD28 SA [20].
Prior to the 2006 trial, Anti-CD28 SA was tested on non-human primates and
rodents to determine the potential for CRS [21]. Although release of cytokines has
been observed in animal models, rarely has it progressed to clinically relevant lev-
4els [22, 23, 24]. Differences in expression of target molecules, regulatory T cells,
cytokines required for inflammatory response, and cell surface receptors among hu-
mans, rodents and non-human primates [25, 26, 27, 28] all indicate that it may not
be appropriate to use animal models to predict CRS in humans.
As a result of this, to further understand CRS in humans, an in vitro assay using
human whole blood was developed and tested by Walker et al. [18]. This assay
was designed to support First-In-Human readiness of mAb treatments assessing the
potential for mAbs to release of cytokines similar to Anti-CD28 SA reaction. The
studies reported in this thesis use results from this assay for further analysis of CRS
using several machine learning approaches.
1.2.2 CRS Problem Definition
The onset of CRS is an important consideration in drug development. Researchers
have applied different machine learning approaches to CRS data from different as-
says [29, 30, 31]. However, the analysis of data has been limited to 1-3 cytokines at
a time and simultaneous multi-dimensional comparisons across a greater number of
cytokines is not common [18]. In this thesis, we apply three (3) machine learning
approaches in combination to multi-dimensional data (12 cytokines) obtained from
Walker’s in vitro assay [18]. These machine learning approaches are (i) Hierarchi-
cal Cluster Analysis (HCA); (ii) Principal Component Analysis (PCA) followed by
K-means clustering; and (iii) Decision Tree Classification (DTC). We try to assess
the potential of mAb-based therapeutics to produce cytokine release similar to that
induced by Anti-CD28 SA. In addition, we apply distance metric learning algorithms
to develop a severity estimation approach that is used to give a more graded severity
levels for different mAb treatments.
51.3 Cardiotocography
1.3.1 Overview
Cardiotocography (CTG), also known as electronic fetal monitoring, is the most
widely used tool for fetal surveillance during pregnancy. CTG monitors changes in
fetal heart rate (FHR) and uterine contractions (UC) during pregnancy [32], and
identifies the occur of fetal hypoxia (short of oxygen). Fetal hypoxia may result
in long term disability or even death during delivery [33]. Therefore, efficient and
effective diagnosis on fetal hypoxia is an important issue.
In obstetrics, CTG provides measurements through either external or internal
methods. In the external method, the FHR and UC are detected by two transducers
placed on the mother’s abdomen. A Doppler ultrasound traducer provides FHR
information and a pressure transducer provides UC data which is recorded on a paper
strip [32]. In the internal method, a catheter is placed in the uterus after a specific
amount of dilation has taken place and provides a more accurate and consistent
transmission of the FHR and UC than external monitoring because factors such as
movement do not affect measurement [34]. CTG shows fetal development and health
information, especially the maturation status of autonomous nervous system [34].
1.3.2 Cardiotocography Problem Definition
Cardiotocography (CTG) is used to evaluate fetal well-being during delivery. In
general, average of FHR, change of FHR, acceleration and deceleration of FHR and
fetal movement are essential parameters on medical diagnosis of fetal hypoxia [35].
Many researchers have been working on different methods to interpret the CTG data
for fetal hypoxia in order to help physicians make clinical decisions [36]. Our problem
here is to analyze a CTG data set consisting of 2126 samples from University of
California-Irvine (UCI) machine learning repository [37]. The data set was classified
6by three expert obstetricians and consensus classification label was assigned to each
sample indicating the status of fetal hypoxia. The goal is to use distance metric
learning approach to build estimation models and to determine the severity of fetal
hypoxia based on the features of the samples.
1.4 Quantitative Structure Activity Relationship (QSAR)
1.4.1 Overview
Quantitative Structure Activity Relationships (QSAR) describe the interaction of
chemical compounds with biological systems making it possible to predict the ac-
tivities/properties of a given compound as a function of its molecular descriptors.
These relationships are essential to toxicological investigations in the development of
pharmaceutical compounds. Biological reactions to new compounds are often inferred
from properties of similar materials whose hazards are already known [38]. During
the development of new pharmaceutical compounds, such chemicals need to be eval-
uated in different biological media where both in vitro and in vivo testing is very
costly and time consuming [39]. In addition, current trends are toward improved un-
derstanding of the chemical mechanisms of toxicological endpoints and consolidation
of toxicological data into databases [38].
1.4.2 Quantitative Structure Activity Relationship (QSAR) Model De-
velopment
The construction of QSAR models is a two step process. The first step is gen-
erating the description of the molecular structure. The second step is multivariate
analysis for correlating molecular descriptors with observed activities/properties. The
model development process is shown in the Figure 1.1, as described by Nantasenamat
et al. [2]. The process starts with observation of the molecular descriptors of the
7data, which are its physiochemical properties. These include electronic, geometrical,
hydrophobic, lipophilicity, solubility, steric, quantum chemical, and topological prop-
erties [2]. Multivariate analysis in this modeling process is the application of machine
learning techniques to discover the relationships between molecular descriptors and
the biological/chemical properties of interest.
Figure 1.1: Schematic overview of the quantitative structure activity relationship
model development process [2]
1.4.3 QSAR Problem Definition
Quantitative structure activity relationships are widely used in drug development.
The molecular descriptors of compounds are from experimental results such as bioac-
tivity assays. A computational QSAR model is built from such compounds so that the
model learns/captures the structural properties of the compounds that are causally
related to their bioactivity [40]. Therefore, QSAR models are commonly formulated
as supervised machine learning problems and researchers have applied different super-
vised classification approaches such as support vector machine [41, 42] and artificial
neural network [43, 44] to analyze QSAR data. In this thesis, we try to determine the
severity of the two families of chemical compounds –Pyrimidines and Triazines [3]–
based on their structural properties. We proposed our distance metric learning ap-
proach for severity estimation which uses a numerical value (between 0 to 1) to
represent the level of severity for the chemical compounds.
81.5 Applications of High-dimensional Molecular Profiling Data to Cancer
Tissue Classification
1.5.1 Overview
With the advancement of genome-wide monitoring technologies, molecular ex-
pression data have become widely used for diagnosing cancer using tumor or blood
samples. When mining molecular signature data, the process of comparing samples
through an adaptive distance function is fundamental but difficult, as such data sets
are normally heterogeneous and high dimensional. In this thesis, we focus on applying
distance metric learning algorithms on the molecular signatures of patient samples
from microarray analysis as well as reducing the computational load when dealing
with high dimensional molecular expression data.
1.5.2 High-dimensional Molecular Profiling Data Problem Definition
Machine learning techniques such as classification and clustering are used for anal-
ysis and interpretation of data obtained from molecular profiling measurements [16,
45]. These data are characterized by a high number of measured variables (m genes)
over a relatively small number of observations (n samples). The number of genes in a
single sample is typically in the thousands and the number of samples is typically in
the hundreds, so the number of feature variables (genes) greatly exceeds the number
of samples. This situation (m >> n) has “high dimensionality” [46] and makes the
application of machine learning techniques challenging. For example, recent studies
have tried to tackle the “high-dimensionality” issue when predicting the existence
of cancer using molecular expressions through sparse-learning based approaches [47].
As molecular signature data become available for more and more patient samples
(e.g. from the national project The Cancer Genome Atlas (TCGA) [48]), measur-
ing the similarity among patient samples becomes critical for mining such signature
9data. Such similarity measures can be used for molecular signature-based retrieval of
similar cancer patient cases when treating a target patient.
In this thesis, we have designed an accurate cancer classification algorithm based
on an extension of “Information-Theoretic Metric learning (ITML)” techniques [49,
50] that is able to provide good assessments of patient similarity, where previous at-
tempts [45, 47] did not fully succeed due to the “curse-of-dimensionality” [46]. Hav-
ing been studied over the past few years [10, 10, 49, 51, 52], distance metric learning
has been applied to practical areas like image recognition [51] and information re-
trieval [53]. This thesis presents two novel extensions of metric learning for the tasks
of sample-level tissue classification and group-level cancer stage determination. The
issue of “small sample, large feature” is addressed through “kernelizing” the learned
metric from ITML or Kernelized Information-Theoretic Metric Learning (KITML).
By learning a nonlinear transformation in the input space implicitly through kernel-
ization, KITML permits efficient optimization and improved learning of a distance
metric. Our two applications of KITML using high-dimensional molecular profiling
data are (1) improving the performance of K-Nearest Neighbor (KNN) classification
for cancer tissue classification and (2) estimating the severity level or stage of a group
of samples.
1.6 Thesis Structure
In Chapter 2, we introduce binary severity estimation for CRS using 1)Hierar-
chical Clustering Analysis (HCA); 2) Principal Component Analysis (PCA) followed
by K-means clustering [54]; and 3) Decision Tree Classification (DTC) [55] to deter-
mine whether a test treatment will have a similar adverse-reaction severity to that of
Anti-CD28 SA. In Chapter 3 we go beyond binary severity estimation using distance
metric learning algorithms which allow us to determine the range of the response
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severities. Here we studied CRS, CTG and two QSAR data sets whose dimensional-
ity was relatively low. The specific algorithm used in Chapter 2 is ITML. In order
to apply the approach to high dimensional data, which would require high computa-
tional cost, we used, instead, a kernel function to make the distance metric learning
more computationally efficient. In Chapter 4, we apply this Kernelized Information-
Theoretic metric Learning (KITML) algorithm to high dimensional microarray data
sets for cancer issue classification. The results for each analysis are given, and the
advantages and drawbacks for each approach are discussed in Chapter 5. The last
chapter presents the conclusion and future work of this thesis.
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2. Binary Severity Estimation for Cytokine Release Syndrome
Binary severity estimation, applied to data of the in vitro assay developed by
Walker et al. [18], determines whether or not the severity of CRS due to a test
treatment is similar to that of Anti-CD28 SA. Walker’s in vitro assay is described first.
Several machine learning algorithms were used here for binary severity estimation of
the assay data. They are: 1)Hierarchical Clustering Analysis (HCA); 2) Principal
Component Analysis (PCA) followed by K-means clustering [54]; and 3) Decision
Tree Classification (DTC) [55]. A comparison of the utility of these approaches for
the analysis of the assay is also presented.
2.1 In Vitro Assay Description and Data Set
For Walker’s assay, blood was drawn aseptically under informed consent1 by
venipuncture using a 21-gauge needle from 44 normal human volunteers into BD
Heparin Vacutainer (San Jose, CA) tubes. Cultures were set up within two (2) hours
of blood collection. Previous reports on these types of assays suggest the need to
immobilize Anti-CD28 for maximal cytokine production [21]. For this purpose, Pro-
tein A coated polystyrene beads were selected. Beads were coated with a saturating
amount of mAb and then distributed to a 96-well culture dish. Each well contained
1×107 beads/well along with 200µl of 1:10 diluted whole blood in RPMI 1640 media.
The cultures were incubated at 37 ◦C for 48 hours. Following incubation, wells
were resuspended and centrifuges at 2500 rpm for 5 min. Supernatant was removed,
transferred to shipping plates, and supernatant plates were frozen at −80 ◦C. Plates
were shipped on dry ice for multiplex analysis.
We used the assay to test the stimulation of human blood from different donors
1Quorum Review IRB approved protocol #NOCOMPOUNDNAP1001
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Table 2.1: List of cytokines release measured in the assay for binary severity estima-
tion
Cytokine Mean (pg/ml) Median(pg/ml) Maximum (pg/ml)
IL-1β 240.8 140.4 1932.3
IL-2 12.0 2.3 406.2
IL-4 2.2 0.5 45.2
IL-6 4897.6 1620.7 39195.5
IL-10 6.3 2.7 100.8
IL-12(p70) 8.3 5.4 55.5
IL-17 22.1 0.1 263.2
IL-18 13.0 10.6 71.1
IFN-γ 4661.2 10.4 90400.57
TNF-α(monometric) 433.8 178.1 3729.62
TNF-α(trimetric) 294.4 131.8 1809.5
where the application of a given treatment (monoclonal antibody (mAb)) on blood
from a particular donor constituted a sample. The concentrations of the 11 cytokines
shown in Table 2.1 were measured for each sample. These concentrations were mea-
sured in triplicate by multiplex enzyme-linked immunosorbent assay (ELISA) using
SearchLightTM technology from Aushon Biosystems (Billerica, MA). Data were re-
ported in pg/ml for each sample and each cytokine. To allow calculation of mean
values and graphic analysis, all concentrations below the level of quantitation were
set to 0.1 [18]. The mean, median, and maximum values of each cytokine for all the
samples are also shown in Table 2.1.
The 7 mAbs and 2 controls used in our study are described in Table 2.2, which
shows the target, manufacturer, number of samples, expected results and class for each
mAb. The “Expected Results” column in Table 2 is based on the clinical literature
(Tocilizumab and Palivizumab) and on the mechanism of action of the research grade
mAb being similar to a compound that has clinical results (for Anti-CD28 SA, Anti-
CD80, Anti-CD22, Anti-IL-1, or Anti-IL-5) [56]. The “class” column is based on the
expected reaction where severe CRS is caused by Anti-CD28 SA; no infusion reactions
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have been reported for the remaining treatments. The data were thus grouped into
two categories, “CD28” and “Safe.” The “CD28” class contained samples only from
cultures treated with Anti-CD28 SA. The “Safe” class contained mAbs that are not
likely to cause CRS or an infusion reaction, and controls.
Table 2.2: List of mAbs and controls used in our CRS detection study
mAb/clone no. Target Manufacturer Samples Expected Results Class
Anti-CD28 SA /
ANC28.1/5D10
CD28 Ancell 152 Severe CRS CD28
Anti-CD80 /
2D10
CD80 Abcam 8 No CRS or Infusion
Reactions
Safe
Anti-CD22 /
LT22
CD22 Abcam 8 No CRS or Infusion
reactions
Safe
Anti-IL-1β /
2805
IL-1β R&D Systems 8 No CRS or Infusion
reactions
Safe
Anti-IL-5 / QS-
5
IL-5 Abcam 8 No CRS or Infusion
reactions
Safe
Tocilizumab IL-6 Re-
ceptor
Roche 8 No CRS or Infusion
Reactions
Safe
Palivizumab RSV Fu-
sion
Medimmune 8 No CRS or Infusion
Reactions
Safe
PBS (Control) - 80 No CRS or Infusion
reactions
Safe
AutoPlasma (Control) - 152 No CRS or Infusion
reactions
Safe
The dataset analyzed in this thesis contains a total of 432 samples that were
measured through 11 runs of the assay. The information for each run is shown in
Table 2.3, including donors in each run, treatments used in each run, number of
samples per treatment, and total number of samples for each run. The sizes of
sample sets corresponding to different treatments are uneven, an observation that
would affect the performance of subsequent analyses.
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Table 2.3: Donor information for 11 runs in the data set
Run ID Donor IDs Treatments
Used
Sample
number per
Treatment
Total
Samples
Run 1
donor #5, donor #9, PBS 4
20
donor #30, donor #36 AutoPlasma 4
Anti-CD28 SA 4
CD80 4
CD22 4
Run 2
donor #1, donor #4, PBS 4
20
donor #27, donor #29 AutoPlasma 4
Anti-CD28 SA 4
CD80 4
CD22 4
Run 3
donor #2, donor #8, donor #10, PBS 8
40
donor #21, donor #22, donor #23, AutoPlasma 8
donor #25, donor #40 Anti-CD28 SA 8
IL-1β 8
IL-5 8
Run 4
donor #1, donor #5, donor #7, PBS 8
24donor #9, donor #10, donor #12, AutoPlasma 8
donor #19, donor #25 Anti-CD28 SA 8
Run 5
donor #1, donor #5, donor #10, PBS 8
40donor #25, donor #36, donor #37, AutoPlasma 16
donor #39, donor #40 Anti-CD28 SA 16
Run 6
donor #1, donor #7, donor #10, PBS 8
56donor #13, donor #19, donor #25, AutoPlasma 24
donor #37, donor #39 Anti-CD28 SA 24
Run 7
donor #6, donor #12, donor #20, PBS 8
24donor #21, donor #28, donor #34, AutoPlasma 8
donor #37, donor #38 Anti-CD28 SA 8
Run 8
donor #13, donor #14 donor #17, PBS 8
40
donor #19, donor #20, donor #24, AutoPlasma 8
donor #26, donor #41 Anti-CD28 SA 8
Tocilizumab 8
Palivizumab 8
Run 9
donor #11, donor #19, donor #15, PBS 8
56donor #31, donor #32, donor #33, AutoPlasma 24
donor #41, donor #43 Anti-CD28 SA 24
Run 10
donor #11, donor #19, donor #15, PBS 8
56donor #31, donor #32, donor #33, AutoPlasma 24
donor #41, donor #43 Anti-CD28 SA 24
Run 11
donor #3, donor #16, donor #17, PBS 8
56donor #18, donor #35, donor #41, AutoPlasma 24
donor #42, donor #44 Anti-CD28 SA 24
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2.2 Hierarchical Clustering Analysis
The first algorithm we used to analyze the treatments of the in vitro assay is ag-
glomerative HCA, implemented in Matlab R© 2012a software (The Mathworks, Natick,
MA). Agglomerative HCA was applied to means of the cytokine samples from each one
of the Table 2.2 treatments. It is a “bottom up” approach which first considers each
treatment as being in its own cluster and then merges pairs of clusters by their dis-
tances from each other. The process repeats until all treatments are within one cluster.
Each treatment was evaluated by using an unweighted group mean with Euclidean
distance as the similarity measurement. The Euclidean distance, dab, between two
means, ma and mb of treatments a and b is defined as dab =
√
(ma −mb)(mb −ma).
2.3 Principal Component Analysis
Principal Component Analysis (PCA) is an algorithm commonly used to reduce
the number of attributes used to represent a set of data. PCA transforms the original
data (which may be given as a function of correlated variables) into linearly uncor-
related attributes, by projecting the original data onto orthogonal components such
that the variance of the projected data is maximized [54]. These orthogonal compo-
nents are obtained by using singular value decomposition of the covariance matrix Σ
associated with the data [57]. The covariance matrix of a vector of random variables
X, is defined as [57]:
Cov(X) = E[(X − E[X])(X − E[X])T ]. (2.1)
We can consider the samples for each attribute as a column vector of random
variables. Hence, we can assemble a matrix M where each row represents one sample
and each column is the difference between one of the attributes and its expected
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value. For our data, there are 11 columns representing 11 cytokine attributes, so M
is of the form
M = [(X1 − E[X1]) ... (X2 − E[X2]) ... · · · · · · ... (X11 − E[X11])]. (2.2)
The covariance matrix can be estimated from the matrix M as the sample covari-
ance matrix Σ,
Σ =
1
n
MTM. (2.3)
The eigenvectors of the covariance matrix Σ are known to characterize the or-
thogonal components (Principal Components). The eigenvalues of Σ are equal to the
variances associated with each Principal Component [54]. PCA was applied to re-
duce the number of attributes used to represent the data. We calculated the variance
associated with each of the Principal Components and chose the components with
the largest variances. We ignored the Principal Components that accounted for small
amount of variance.
The best results from PCA are obtained for datasets whose attributes have similar
dynamic ranges [54]. In our case, the data vary greatly, as seen in column 4 of
Table 2.1, so we applied a logarithmic transformation on the data before proceeding
with the analysis. This transformation may be used when the attributes show a linear
or nearly-linear relationship between the standard deviation and the mean for each
treatment [58][59], which our data do exhibit (as shown in Chapter 5).
2.4 K-means Clustering
K-means clustering, which we applied to the data after PCA, assigns the n ob-
servations in a dataset into k clusters. Each observation is assigned to the cluster
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whose mean is the nearest to that observation. The standard K-means clustering
algorithm is based on alternating two procedures [60]. The first procedure is the
assignment step, which assigns each observation to the cluster whose mean yields the
least within-cluster sum of distances. The second procedure is the calculation of new
cluster means based on the assignments. The process stops when no reassignment
of an observation to a cluster would minimize the within-cluster sum of distances
between samples and the mean of each cluster. The Euclidean measure was used here
to calculate the distance between observations.
2.5 Decision Tree Classification (DTC)
The C4.5 DTC algorithm [55] implemented in the Weka 3.6.6 software [61] (Uni-
versity of Waikato, Hamilton, New Zealand) was also used to analyze the dataset.
This is a supervised machine learning algorithm, meaning that a correctly-labeled
data set is required to “train” the algorithm before the algorithm can be applied to
unknown data. Each observation in the dataset is defined by a collection of measured
attributes (in our case cytokine levels) and a corresponding group or class label. The
algorithm defines a set of rules that assign each observation to a corresponding class.
The input to the algorithm is the collection of attributes for a given observation, and
the output is the assigned class for that observation.
The DTC algorithm uses training data to infer rules that describe the correspon-
dence between input attributes and the classes into which they are associated. The
algorithm applies a “divide and conquer” approach, resulting in an iterative process
that starts by analyzing each attribute from the training data separately from the
others. It calculates the information gain for each attribute with respect to the pos-
sible class outcomes present in the training data [55]. The attribute with the highest
information gain is denoted as the “root node.” This attribute is used to make the
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first separation of the data samples in a process called “branching” that assigns a
“branch” to each sample according to the attribute value present in the sample.
After the first branching operation, the samples belonging to a specific branch
may be associated with a class if all the samples in the branch have the same class
label. In this case, the algorithm is said to have researched a “leaf node” denoted
by the label associated with the corresponding class. If the samples in the branch
have different class labels, the sample are analyzed further to find the attribute with
the highest information gain. This process is repeated until all observations in the
dataset are assigned a class.
Since the attributes in our dataset have continuous values, it was necessary for the
algorithm to define thresholds that separate the possible attribute values into discrete
groups which can then be associated with a corresponding class. Each threshold is
chosen by iteratively calculating information gains for certain threshold candidates in
the data from the attribute being analyzed (the method for generating threshold can-
didates is described in [62], Section 6.1). The candidate with the highest information
gain is used to split the values of the attributes and build the Decision Tree.
The rules created by the algorithm are displayed using a tree structure consisting
of test nodes and branches. Each node represents the testing of a rule applied to a
certain attribute. The branches represent the possible outcomes from the test, and
point to either a class label or to another node for further testing. The top node in
the tree is the “root node,” which represents the testing of the most relevant attribute
obtained by the algorithm. The class assigned for a given sample is denoted by a “leaf
node,” which is located at the bottom of the tree and contains the label assigned to
a given sample.
The DTC algorithm analyzes all the attributes in the training set and selects the
best attribute that maximizes the information gain as the root node. This attribute
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is considered the most relevant for classification among all attributes [55]. The sec-
ond most relevant attribute is found by removing the attribute in the root node and
applying the algorithm to the remaining attributes [63]. The new root node is consid-
ered the second most relevant attribute for classification. This process is continued
until all attributes were considered.
2.6 The DTC Model Construction (Definition of Training Data Sets and
Test Data Set)
The DTC model is constructed using the data set shown in Table 2.3. In order to
build and validate the model, we divided the data into training data and test data.
We defined two training data sets using some or all of the 264 samples from 32 donors
in runs 1-8 shown in Table 2.3. The remaining 168 samples from 15 donors in runs
9-11, were reserved as test data set. Before applying the test data from runs 9-11 we
ran cross validations with the two training data sets to determine the accuracy of our
models.
Training data set 1, consisting of 216 samples shown in Table 2.4, was assembled
using only the control samples for the “Safe” class and the Anti-CD28 SA samples for
the “CD28” class. The use of these data for the training set is expected to maximize
the difference between samples from the two classes. For training data set 2, consisting
of the 264 samples shown in Table 2.4, we used additional mAbs in the “Safe” class.
The “Safe” class included Tocilizumab [64] and Palivizumab [65], two mAbs that
were tested clinically and have shown no CRS reactions, and four (4) research-grade
compounds that were not tested clinically but have the same target as mAbs that were
tested clinically. The four research-grade compounds are assumed - like their clinical
counterparts - not to cause CRS reactions. They were: 1) CD80 which may be similar
to Galiximab [66]; 2) CD22 which is similar to Epratuzumab [66]; 3) IL-1β which is
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similar to Canakinumab [67]; and 4) IL-5 which is similar to Mepolizumab [68]. The
controls, PBS and AutoPlasma, were also included in the “Safe” class. The test data
set was selected from the 168 samples in runs 9-11 shown in Table 2.3. Since there
are 3 common donors (donor #17, donor #19 and donor #41) between runs 1-8 and
runs 9-11, the 42 samples of these three donors were removed from the test data set,
leaving 126 samples in the test data set, as shown in Table 2.6. The test data samples
therefore came from different donors than those used in training data sets 1 and 2,
and could be used to assess the ability of the DTC models to classify new data.
Table 2.4: Training data set 1 for DTC
Class MAbs and controls # samples
Safe PBS(56) 136
AutoPlasma(80)
CD28 Anti-CD28 SA(80) 80
Table 2.5: Training data set 2 for DTC
Class MAbs and controls # samples
Safe
PBS(56)
184
AutoPlasma(80)
Tocilizumab (8)
Palivizumab(8)
CD80(8)
CD22(8)
IL-1β(8)
IL-5(8)
CD28 Anti-CD28 SA(80) 80
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Table 2.6: Test data set for DTC
Class MAbs and controls # samples
Safe PBS(18) 72
AutoPlasma(54)
CD28 Anti-CD28 SA(54) 54
2.7 Cross Validation Method for Estimating DTC Accuracy
In order to estimate the classification accuracy of the DTC model on new data
with unknown class labels, the following cross validation methodology was used: the
entire training data set was split randomly into two sets: one set was used for train-
ing (2/3 of the data) and one set was used for cross validation (1/3 of the data). To
prevent samples from the same donor from appearing in both sets, we grouped the
samples by donor, and then randomly selected donors whose samples numbers added
up to one third of the total number of samples. The samples from the rest of the
donors were used for training the DTC model. This process was repeated multiple
times until samples from all the donors were considered equally often for both train-
ing and validation. The classification accuracy estimate was defined as the average
classification accuracy for all the training/testing set partitions.
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3. Severity Estimation using Distance Metric Learning
In many circumstances, the binary determination of severity may be of limited
value, and we may be interested in a multi-class and more graded determination of
the level of severity. For such determination we propose the Severity Estimation
using Distance Metric Learning (SE-DML) approach. SE-DML uses distance metric
learning algorithms to develop multi-level of severity assessment. The four data sets
used in the evaluation are Cytokine Release Syndrome (CRS), Cardiotocography
(CTG), Pyrimidines and Triazines data sets.
3.1 Problem Formulation
The problem of estimating the disease’s severity can be divided into two stages:
(1) choosing the most medically relevant set of features describing the disease of
interest and (2) combining these variables in a functional form (model) which is able
to provide the most accurate severity estimation for the disease [12]. Focusing on the
stage (2), here we proposes to tackle SE-DML. More specifically, we have observed
that in most cases of biomedical severity estimation in practice, the reference data
(i.e. the sample groups with known severity) normally include only positive (e.g.
least severe disease state) and negative controls (e.g. most severe disease state). The
reason is that in biomedical experiments such as blood assay, clinical trials and animal
testing, many researchers utilize and label positive and negative controls to verify the
success of their experiments. Thus SE-DML aims to solve the following problem.
• We are given a data set with multiple samples groups associated with different
severity levels of a disease. Some sample group severity levels are known (posi-
tive and negative control groups) and some are unknown. The main goal is to
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estimate the severity of unknown sample groups based on their relationship to
the known ones.
Samples in the same group should match to the same level of severity. For example,
a “group” could describe a certain disease state.
Figure 3.1: Problem formulation: the severity levels of positive control E+ and neg-
ative control E− are known. The severity level y?i of an unknown sample group E
?
i is
estimated based on its distances to the two controls.
Our setup includes a data set of m-dimensional samples about a certain biomed-
ical condition. These samples belong to n sample groups {E1, . . . ,En}, where each
sample group E ∈ RpE×m contains pE samples {x1, . . . ,xpE} and corresponds to a
severity level yi of this biomedical condition. We assume that the severity levels yi
are numerical values between 0 and 1, with 0 being the least severe and 1 being the
most severe. Among these n sample groups, some have known severity levels. As we
mentioned above, in most cases, the sample groups with known severity are positive
and negative controls. Here we define y+ = 1 for positive control E+, whereas y− = 0
for negative control E−. The objective is to estimate the severity level y?i of an un-
known sample group E?i based on its distances to E
+ and E−. The problem definition
of SE-DML is illustrated in Figure 3.1.
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3.2 Basic Distance Metric Learning
Metric learning methods try to learn a Mahalanobis distance defined in expression
(3.1), where A is a positive semi-definite m by m matrix of parameters learned from
data. The learning process usually relies on pairwise constraints between sample
points as training signals: (1) equivalent constraints (equation 3.2), which state that
a given pair of data points are semantically similar and should be close together in
the learned metric; and (2) inequivalent constraints (equation 3.3), which indicate
that the given pairs of samples are semantically dissimilar and should not be close
together in the learned metric [69].
dA(xi,xj) =
√
(xi − xj)TA(xi − xj) (3.1)
S = {(xi,xj)|xi and xj are similar} (3.2)
D = {(xi,xj)|xi and xj are dissimilar} (3.3)
A commonly used formulation of distance metric learning [10] converts the above
constraints to a convex programming task to learn the parameter matrix A:
min
A∈Rm×m
∑
xi,xj∈S
dA(xi,xj) (3.4)
s.t.
∑
xi,xj∈D
dA(xi,xj) ≥ 1, and A  0.
The positive semi-definite constraint A  0 is required to guarantee the learned
distance between any two points (parameterized by A) cannot be negative and satisfies
the triangle inequality.
For our targeted task handling a set of sample groups mapping to a range of sever-
ity levels, it is natural to think that one can calculate the distances between samples
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with unknown severity to samples with known severity, in order to estimate the un-
known severity. But the commonly used Euclidean distance metric may not capture
the fact that samples from the positive control E+ should be far from samples from
the negative control E−. The basic idea of distance metric learning is maximizing the
distances between dissimilar sample groups, and minimizing the distances between
samples in the same group or among similar groups. Specifically, the learned met-
ric based on positive control and negative control should give a maximum distance
d(E+, E−) between these two controls. The distances between a sample group E?i
with unknown severity level and two controls can then be measured based on this
learned metric. These distances should be proportional to d(E+, E−) and can be
combined to locate the position of this unknown group between the two controls,
where the position indicates the severity level.
3.3 Overall Framework
The objective of SE-DML approach is to estimate the severity levels of n unknown
sample groups {E?1, . . . ,E?n} based on positive control E+ and negative control E−,
which are known beforehand. The set of equivalence constrains S (equation 3.2)
consists of pairs of samples within E+ or E−. The set of inequivalent constrains D
(equation 3.3) consists of pairs of samples from different controls – one sample from
E+ and one sample from E−. A Mahalanobis distance metric is then learned based on
these constrains using the distance metric learning method described in Chapter 3.4.
Based on the learned metric, the distances of the unknown groups to the controls are
calculated and will be transformed to severity levels y as described in Chapter 3.5.
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3.4 Information-Theoretic Metric Learning (ITML)
Given a distance metric parameterized by A, a corresponding multivariate Gaus-
sian distribution could be expressed for describing samples where A−1 is the covariance
matrix of the distribution, i.e.,
Pr(x|A) = 1
(2pi)m/2|A|1/2 exp(−
1
2
xTA−1x). (3.5)
Considering the Euclidean distance (i.e., distance metric with identity matrix A0 =
I) works well as a baseline empirically, we regularize the learned metric matrix A
with A0. Probabilistically, this equals to minimize the distance between the two
corresponding Gaussian distributions, denoted by Pr(x|A) and Pr(x|A0). Typically,
Kullback-Leibler (KL) divergence [70] is used to measure the distance between two
distributions, thus the distance between Pr(x|A) and Pr(x|A0) is given by,
d(A0||A) = KL(Pr(x|A0)||Pr(x|A))
=
∫
Pr(x|A0) log Pr(x|A0)
Pr(x|A) dx. (3.6)
Then the log determinate (LogDet) formulation is used to simplify the d(A0||A) in a
closed form:
d(A0||A) = 1
2
(tr(A−1A0) + log|A| − log|A0| −m), (3.7)
where m is the dimensionality of the data. Suppose the means of the Gaussian
distribution is 0, the proof for equation 3.7 is as follow,
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d(A0||A) (3.8)
= KL(Pr(x|A0)||Pr(x|A))
=
∫
Pr(x|A0) log Pr(x|A0)
Pr(x|A) dx
=
∫
[log(Pr(x|A0))− log(Pr(x|A))]Pr(x|A0)dx
=
∫
[
1
2
log
|A|
|A0| +
1
2
xTA−10 x+
1
2
xTA−1x]Pr(x|A0)dx
=
1
2
log
|A|
|A0| −
1
2
tr{E(xTx)A−10 +
1
2
E(xTx)A−1}
=
1
2
log
|A|
|A0| −
1
2
tr{Im}+ 1
2
tr{A−1A0}
=
1
2
(tr(A−1A0) + log|A| − log|A0| −m)
Based on the above formulation, Davis et al. proposed ITML [49][50] to tackle
metric learning by minimizing the LogDet divergence (equation 3.7) plus side con-
straints (equivalent or inequivalent). The constraints used in ITML are similar to
those described in Chapter 3.2, in which for two similar samples, their learned dis-
tance is constrained to be smaller than a given upper bound, i.e., dA(xi,xj) ≤ u for a
parameter u, and, for two samples that are known to be dissimilar, dA(xi,xj) ≥ l for
a parameter l. The objective is to learn a distance metric parameterized by parameter
matrix A. To solve this optimization, ITML uses the so-called Bregman projections
for solving a strictly convex optimization with respect to multiple linear inequality
constraints. Using this simple first-order technique developed in [71], ITML repeat-
edly computes Bregman projections of the current solution onto a single constraint
via the following update
At+1 = At + βAt(xi − xj)(xi − xj)TAt, (3.9)
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where β is the projection parameter (Lagrange multiplier) corresponding to the cur-
rent constraint. It is positive for similar pairs and negative for dissimilar pairs.
3.5 Severity Estimation for a Sample Group
After learning a distance metric, we can calculate the distances between a sample
x?i (with an unknown severity level y
?
xi
) to the positive control E+ and negative control
E−. Thus the distance between x?i and E
+ is defined as :
dA(x
?
i ,E
+) = (
∑
xk∈E+
x+k
|E+| − x
?
i )
TA(
∑
xk∈E+
x+k
|E+| − x
?
i ). (3.10)
Similarly, the distance between x?i and E
− is defined as :
dA(x
?
i ,E
−) = (
∑
xk∈E−
x−k
|E−| − x
?
i )
TA(
∑
xk∈E−
x−k
|E−| − x
?
i ). (3.11)
These two distances are used together to determine the severity level y?xi (equa-
tion 3.12) for a sample x?i . If y
?
xi
is closer to 0, the severity level of x?i is more
similar to that of the negative control. If y?xi is close to 1, the severity level of x
?
i is
more similar to that of the positive control.
y?xi =
dA(x
?
i ,E
−)
(dA(x?i ,E
+) + dA(x?i ,E
−))
. (3.12)
The severity y?i of E
?
i is then defined as
y?i =
∑
x?i∈E?i
y?xi
|E?i |
. (3.13)
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Table 3.1: List of cytokines release measured in the assay for SE-DML
Cytokine Mean (pg/ml) Median(pg/ml) Maximum (pg/ml)
IL-1β 457.68 222.37 4550.80
IL-2 27.07 2.34 2636.76
IL-4 1.69 0.38 45.20
IL-6 7875.14 2591.21 88002.05
IL-8 24106.95 13859.18 427144.20
IL-10 15.09 3.50 636.68
IL-12(p70) 8.57 5.88 91.37
IL-17 25.11 0.10 2410.40
IL-18 14.36 11.42 131.41
IFN-γ 3222.47 36.68 90400.57
TNF-α(monometric) 455.00 267.08 3729.62
TNF-α(trimetric) 306.93 173.67 1819.08
3.6 Cytokine Release Syndrome Data Set
This CRS data set used here is generated by the same in intro assay as described in
Chapter 2.1 with more treatments. The assay measured the concentrations of the 12
cytokines shown in Table 3.1. Data were reported in pg/ml for each sample and each
cytokine. To allow calculation of mean values and graphic analysis, all concentrations
below the level of quantitation were set to 0.1 [18].
The data set from the in vitro assay contains a total of 30 treatments listed
in Table 3.2. Each treatment has a different number of samples indicated in the
parenthesis. There are a total of 711 samples in the data set. For each sample, the 12
cytokines described in Table 3.1 are measured as features. The 30 treatments have
been roughly classified into 5 groups based on the severity descriptions of CRS found
in clinical literature, which ranges from the most severe CRS caused by anti-CD28
SA to no reaction at all [56][72]. The 5 groups are negative control(E−), safe(E?1),
middle(E?2), severe(E
?
3) and positive control(E
+). The negative control group has no
CRS reaction at all. The safe group contains treatments not likely to cause CRS or
an infusion reaction. The middle group contains treatments that could potentially
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Table 3.2: List of treatments (mAbs) used in the CRS data set for SE-DML. Each
treatment has a different number of samples indicated in the parenthesis
Negative Control(E−) Safe(E?1) Middle(E
?
2) Severe(E
?
3) Positive Control(E
+)
AutoPlasma (152) Adalimumab (16) Anti-VEGF (8) CD2 (16) Anti-CD28 SA (152)
PBS (80) Alemtuzumab (8) Basiliximab (8) CD28-Biol (8) LPS (80)
CD11a (8) IL-12 (8) CD28-SB (8)
CD22 (8) KV1D261-1.003 (8) CD20 (23)
CD80 (8) KV1D261-20.001 (8) CD3 (16)
Cetuximab (8) Panitumumab (8) CD3/CD28 (8)
IL-1b (8) CD4(8)
IL-5 (8) CD40 (8)
IL-6 (8)
IL-6-B-E8 (8)
Palivizumab (8)
Tocilizumab (8)
cause infusion reactions, but milder than the reactions caused by the treatments in
severe-CRS class. The severe-CRS group contains treatments that will cause severe
CRS. The positive control group will cause the most severe CRS.
3.6.1 Evaluation Setup
To reduce the differences in the dynamic ranges of the 12 features, the data are
z-score transformed first. The z-score transformation is defined as z = x−µ
σ
, where
x is a raw data sample, µ is the means of the sample population and σ is the stan-
dard deviation of the sample population. The distance metric parameterized by A is
learned based on the positive controls (E+) and negative controls (E−) in Table 3.2.
The constrained sample pairs are formulated by the samples within the two control
groups. The lower and upper bounds of the right hand side of the constraint (l and u)
described in Chapter 3.4 are the 5th and 95th percentiles of the observed distribution
of distances between pair of points within two control groups, respectively.
3.7 Cardiotocography Data Set
Cardiotocography (CTG) is the most widely used tool for fetal surveillance. The
data set contains 2126 fetal CTG samples that were classified by three expert obste-
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Table 3.3: Number of samples in each class of CTG data set
Class Number of Samples
Normal 1655
Suspect 295
Pathologic 176
tricians and a consensus classification label assigned to each of them [37][73]. The
classification labels are based on the severity of fetal abnormal states: normal, suspect
and pathologic. The number of samples for each class are shown in Table 3.3. The
21 diagnostic features for each sample are shown in Table 3.4.
3.7.1 Evaluation Setup
The CTG data set is normalized through each feature by z-score transformation.
The z-score transformation is defined as z = x−µ
σ
, where x is a raw data sample, µ is
the means of the sample population and σ is the standard deviation of the sample pop-
ulation. To evaluate proposed SE-DML approach, a 10-fold cross validation strategy
was used. Since there are only 3 classes in the data set, in each iteration of the 10-fold
cross validation, 90% of the normal class samples and pathologic samples were used
to formulate negative controls E− and positive controls E+ which were used to learn
distance metric parameterized by A. The constrained sample pairs are formulated by
the samples within E− and E+. The lower and upper bounds of the right hand side
of the constraint (l and u) described in Section 3.4 are the 5th and 95th percentiles
of the observed distribution of distances between pair of points within positive and
negative controls data, respectively. The remaining 10% samples of these two classes
and the entire suspect class samples {E?1,E?2,E?3} are used to test the performance.
The average results of the 10 iterations are used as the final evaluation results.
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Table 3.4: The 21 diagnostic features of CTG data set
Index Feature
1 LB - FHR baseline (beats per minute)
2 AC - number of accelerations per second
3 FM - number of fetal movements per second
4 UC - number of uterine contractions per second
5 DL - number of light decelerations per second
6 DS - number of severe decelerations per second
7 DP - number of prolongued decelerations per second
8 ASTV - percentage of time with abnormal short term variability
9 MSTV - mean value of short term variability
10 ALTV - percentage of time with abnormal long variability
11 MLTV - mean value of long term variability
12 Width - width of FHR histogram
13 Min - minimum of FHR histogram
14 Max - Maximum of FHR histogram
15 Nmax - number of histogram peaks
16 Nzeros - number of histogram zeros
17 Mode - histogram mode
18 Mean - histogram mean
19 Median - histogram median
20 Variance - histogram variance
21 Tendency - histogram tendency
3.8 Quantitative Structure Activity Relationship Data Sets
Quantitative Structure Activity Relationships (QSAR) relate to the interaction
of chemical compounds with biological systems. These relationships are essential
to toxicological investigation in the development of pharmaceutical compounds. Our
severity estimation approach is used to predict the toxicity of two families of chemical
compounds, Pyrimidines and Triazines, based on their QSAR data sets [3], where each
compound has 5 levels of severity as class labels.
In forming a QSAR for a series of chemical compounds, we consider the com-
pounds to have a common structure onto which substituent groups are added [1].
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Table 3.5: Physico-chemical attributes of substituent in Pyrimidines and Triazines [1]
Attribute name Notation
Polarity PL
Size SZ
Flexibility FL
Hydrogen-bond donor HD
Hydrogen-bond acceptor HA
pi bond acceptor ΠA
pi bond donor ΠD
Polarizability PO
δ effect δ
Branching BR
Substituent groups are groups of atoms substituted in place of a hydrogen atom on
the parent chain of a hydrocarbon and represent physico-chemical attributes. The
physico-chemical attributes of the substituent in Pyrimidines and Triazines are shown
in Table 3.5. These physico-chemical attributes in the Table 3.5 are considered as
features that related to the two compounds’ toxicity. The SE-DML approach devel-
oped here was used to capture the relationships between features and compounds’
toxicity. In Pyrimidines there are three possible regions for a substituent as shown
in Figure 3.2, and with nine features for each region (Branching was not used), each
sample in the Pyrimidines data set has an feature vector of 27 elements. In ad-
ditional, each sample has a real value activity class label denoted as the severity
level. For example, a sample in the Pyrimidines set with a CI substituted at po-
sition R3, OCH3 group substituted at position R4, and a CI group substituted at
position R5, is represented by the feature vector shown in Figure 3.3. The first 9
features are the physico-chemical attributes of CI substituent at position R3 (The
attributes in Table 3.5 excluding the last attribute Branching). The second 9 features
are the physico-chemical attributes of OCH3 position R4. The third 9 features are
the physico-chemical attributes of CI position R5. The last number, 2, indicates the
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severity level [3]. For the Triazines data set, compounds have six possible regions for
a substituent and there are 10 features for each regions. So each sample has a total
of 60 features.
Figure 3.2: Structure of the Pyrimidines where substitutions can occur at positions
R3, R4 and R5 [1].
3.8.1 Evaluation Setup
The activity values that indicate the toxicity levels for both Pyrimidines and
Triazines data sets were discretized into five intervals [3]. These five intervals are
denoted as five sample groups: {E−,E?1,E?2,E?3,E+}, with severity levels y− < y?1 <
y?2 < y
?
3 < y
+. Each data set has been randomly separated into control and test
partitions. The control partition is used to learn a distance metric, where, E− is
negative control and E+ is positive control. In the test partition, the E?1, E
?
2 and
E?3 sample groups are used for severity estimation in order to evaluate our SE-DML
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Figure 3.3: Feature vector for a sample in Pyrimidines data set. The first 9 features
are the physico-chemical attributes of CI substituent at position R3 (The attributes
in Table 3.5 excluding the last attribute Branching). The second 9 features are
the physico-chemical attributes of OCH3 position R4. The third 9 features are the
physico-chemical attributes of CI position R5. The last number, 2, indicates the
severity level [3].
approach. The partitioning was repeated 20 times with replacement1 and the number
of samples for both control and test partitions are shown in Table 3.6. The average
severity levels of E?1,E
?
2,E
?
3 are used as the final results.
Table 3.6: Characteristic of the two QSARs data sets: the number of features and
number of samples for the two partitions
Data Sets Number of
Samples
in Control
Partition
Number of Sam-
ples in Test Parti-
tion
Number of features
Pyrimidines
(74)
50 24 27
Triazines
(186)
100 86 60
1The data sets and the partitions generated are available to download at
http://www.gatsby.ucl.ac.uk/ chuwei/ordinalregression.html
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3.9 Algorithm Comparison
The evaluation setup for all four datasets (Cytokine Release Syndrome (CRS),
Cardiotocography (CTG), Pyrimidines and Triazines data sets) are shown in Ta-
ble 3.7. We implement the following five approaches to compare their ability to
estimate the severity on these four data sets:
1. Severity Estimation using Distance Metric Learning (SE-DML) where we use
Information-Theoretic Metric Learning (ITML) as the metric learning algo-
rithm;
2. Euclidean distance under the same framework of SE-DML; we use this approach
to compare how learned distance metric improve the performance of severity
estimation over commonly used distance metric;
3. Large Margin Nearest Neighbors (LMNN), another state-of-the-art metric learn-
ing algorithm [52]. We use LMNN under the same framework of SE-DML;
4. Linear Regression where we use E+ and E− with severity level 1 and 0, re-
spectively, to build the regression model to predict severity levels of individual
samples in each test class {E?1, E?2 and E?3};
5. Support Vector Regression, using the same setup as linear regression, imple-
mented by libsvm v3.18 with radial basis function kernel function [74] on Matlab R© 2012a
software (The Mathworks, Natick, MA).
3.10 Evaluation Criteria
We use two evaluation criteria for comparing the five approaches described above.
The first is the order of severity levels of each test group. Second, in order to mea-
sure how well each sample’s estimated severity level lies within its group, we use a
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Table 3.7: Evaluation setup of four data sets. The positive control E+ and negative
control E− are used to learn distance metric. The three middle groups E?1, E
?
2 and
E?3 are used as test data.
Levels of Severity
Data Sets E− E?1 E
?
2 E
?
3 E
+
CRS AutoPlasma
& PBS
Safe
treatments
Middle
treatments
Severe-CRS
treatments
Anti-CD28
SA & LPS
CTG 90%
Normal
10%
Normal
100%
Suspect
10%
Pathologic
90%
Pathologic
Pyrimidines Level 1 Level 2 Level 3 Level 4 Level 5
Triazines Level 1 Level 2 Level 3 Level 4 Level 5
silhouette coefficient [75], which contrasts the average distance of a sample to other
samples in the same cluster with the average distance to samples in other clusters.
The silhouette coefficient is defined in equation 3.14, where ai is the average distance
from the ith sample to the other samples in the same cluster and bi is the minimum
average distance of the ith sample to samples in a different cluster which is the closest
to the cluster of ith sample. This coefficient has a value between -1 and +1 where a
higher value, closer to +1, indicates that the sample is well-matched to its own group,
and poorly-matched to other groups.
si =
bi − ai
max(ai, bi)
(3.14)
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4. Application of High-dimensional Molecular Profiling Data to Cancer
Tissue Classification
Cancer molecular profiling data are typically high-dimensional and make machine
metric learning quite challenging. When given a data set X = [x1,x2, . . . ,xn], where
each xi ∈ Rm,Information-Theoretic Metric Learning (ITML) introduced in previous
chapter will learn a distance metric parameterized by a m × m matrix A. If the
dataset is high-dimensional, where the feature number m is relatively large in gene
microarray data set, ITML needs to estimate m2 parameters in A which is certainly
not ideal considering the computational load.
4.1 Kernelized Information-Theoretic Metric Learning (KITML) for High-
Dimensional Data
The commonly formulation of distance metric learning [10] is a convex program-
ming task that tries to learn the parameter matrix A:
min
A∈Rm×m
∑
xi,xj∈S
dA(xi,xj) (4.1)
s.t.
∑
xi,xj∈D
dA(xi,xj) ≥ 1, and A  0.
The positive semi-definite constraint A  0 is required to guarantee the learned
distance between any two points (parameterized by A) cannot be negative and satisfies
the triangle inequality.
ITML solves the metric learning problem as minimizing the relative entropy be-
tween two multivariate Gaussians distribution under side constraints. Two samples
are similar if the Mahalanobis distance between them is smaller than a given upper
39
bound, i.e., dA(xi,xj) ≤ u for a relatively small value of u. Similarly, two samples
are dissimilar if dA(xi,xj) ≥ l for a relatively large l. The objective is to learn a
Mahalanobis distance parameterized by A which should be as close as possible to a
prior distance function A0, e.g. Euclidean distance. The closeness of the solution to
the prior is measured by the Kullback-Leibler (KL) divergence [70]:
d(A0||A) =
∫
Pr(x|A0) log Pr(x|A0)
Pr(x|A) dx. (4.2)
The optimization problem for ITML can be solved by the connection between
KL-divergence and the LogDet divergence. Therefore, the optimization problem can
be expressed as following [49, 50],
min
A
d(A||A0) (4.3)
s.t. tr(A(xi − xj)(xi − xj)T ) ≤ u, (i, j) ∈ S,
tr(A(xi − xj)(xi − xj)T ) ≥ l, (i, j) ∈ D,
A  0.
Given a microarray data set X = [x1,x2, . . . ,xn], each xi ∈ Rm is a data vector
with m features. ITML will try to learn a distance metric parameterized by m ×m
matrix A. Since m is relatively large in microarray data set, ITML will be slow
under this situation. To adapt ITML for datasets with n  m, we employ the
kernel function and present the Kernelized Information-Theoretic Metric Learning
(KITML) for learning a kernel matrix K = XTAX. Under this formulation, we only
need to estimate n×n parameters in the matrix K which is much smaller than m×m
parameters in the original A matrix. The distance between two points based on K
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can be denoted as
dA(xi,xj) = (ei − ej)TK(ei − ej), (4.4)
where ei and ej are the unit basis vectors in which only the entry i or j is 1 and the
rest are 0.
The optimization problem is to search for K that satisfies the similar/dissimilar
side constraints as well as minimizing the KL divergence. Similarly, A0 is transformed
to kernelized K0 = X
TA0X for the regularization distribution.
min
A
d(K0||K) (4.5)
s.t. (ei − ej)TK(ei − ej) ≤ u, (i, j) ∈ S,
(ei − ej)TK(ei − ej) ≥ l, (i, j) ∈ D,
K  0.
The parameters, upper bound u and lower bound l are determined by the distribution
of the data. The optimization is performed through Bregman projections [71], where
in each iteration, a constraint (i, j) ∈ S or (i, j) ∈ D is picked to update the matrix
K. The Bregman projection update is similar to equation 3.9 and could be denoted
as,
Kt+1 = Kt + βKt(ei − ej)(ei − ej)TKt, (4.6)
where β is the same as that in equation 3.9.
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4.2 Calculating Distance in KITML for High-dimensional Microarray
Data
When using KITML to improve the classification cancer microarray data, the
distance metric parameterized by kernel matrix K is learned by certain samples that
are considered as training data. During the testing phase, we need to calculate
distances among samples that might not be covered by the kernel K, thus, we could
not use equation 4.4 directly. Through a few steps of derivation and a theorem
from [51], we can construct A in a closed-form from K in the following manner.
A = αI +XTXT , (4.7)
where T = K−10 (K − αK0)K−10 , (4.8)
Here α is suggested to be 1 [51]. We can calculate the distance between any two
“high-dimensional” sample points using an implicit representation of A through kernel
evaluation as, namely
dA(xi,xj)
2 = (xi − xj)T (I +XTXT )(xi − xj) (4.9)
= (xi − xj)T (xi − xj) + (xi − xj)TXTXT (xi − xj).
Instead of learning m2 parameters in A (m is the number of features), only n2 pa-
rameters (n is the number of samples) need to be learned by using the above kernel
formulation. KITML thus permits efficient optimization and low storage through
equation 4.6. At the same time, equations 4.8 and 4.9 make the evaluation of the
learned distance metric (i.e. calculating distances) efficient as well.
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4.3 Sample-level Tissue Classification with K-Nearest Neighbor (KNN)
KITML
K-Nearest Neighbor (KNN) classification is a commonly used classification al-
gorithm for cancer data. For high-dimensional molecular signature data, when us-
ing metrics like Euclidean distance, KNN is often inferior to more sophisticated ap-
proaches such as Support Vector Machines [16]. In this thesis, we use KITML to
actively learn a distance metric to improve the performance of KNN-driven cancer
classification. KITML also reduce the heavy computation burden of distance metric
learning through kernelization. The process works as following:
1. Compute the distances of a test sample xi to the labeled training samples yi
using equation 4.9.
2. Order the training samples by increasing distances from the test sample.
3. Use cross validation to find the optimal number of nearest neighbors, k, based
on training samples.
4. Use majority vote (or inverse distance weighted average based on k nearest
neighbors) to determine the class of the test sample xi.
4.3.1 Other Algorithms compared with KITML
We compared KITML performance with several state-of-the-art algorithms.
1. KNN Classification with distance metric learned by ITML* Directly
learning distance metric from high-dimensional data set by ITML is quite slow.
Our data sets originally contain between 1000 and 4000 features so we first
use a variance feature selection process to obtain a reduced feature set of size
100. The metric learning process and KNN classification are based on these 100
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features with the highest variance. We denote this ITML algorithm using the
100 selected features as ITML*.
2. K-Nearest Neighbor (KNN) Classification with Euclidean Distance
Here we use Euclidean distance as a baseline to illustrate that KITML can
improve KNN classification.
3. Multi-class Support Vector Machine (SVM) with Linear Kernel SVM
often achieves superior classification performance compared to other learning
algorithms across most domains and tasks [16]. SVM maps data to a higher
dimensional space via a kernel function and then solves an optimization problem
to find the maximum-margin hyperplane that separates training samples. The
test samples are classified based on their separation by hyperplane. In this
thesis, we compare SVMs implemented by libsvm v3.18 [74] using a linear kernel
K(x, y) = xTy, where x and y are samples with gene expression values.
4. Multi-class Support Vector Machine (SVM) with Radial Basis Func-
tion Kernel We compare SVM using a radial basis function (RBF) kernel
K(x, y) = exp(−γ|x − y|2), where x and y are samples with gene expression
values and γ is kernel parameter. It was also implemented by libsvm v3.18 [74].
5. Large Margin Nearest Neighbor Classification Large Margin Nearest
Neighbor (LMNN) [52] is a popular metric learning algorithm that learns a
Mahalanobis distance metric for KNN classification from labeled examples. It
aims at improving KNN classification by exploiting the local structure of the
data. In this algorithm, the distance metric is trained with the goal that k
nearest neighbors always belong to the same class while examples from differ-
ent classes are separated by a large margin. The algorithm attempts to increase
the number of training examples with this property by learning a linear trans-
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formation of the input space that precedes KNN classification using Euclidean
distances [52]. The loss function minimized by the linear transformation consists
of two terms. The first term penalizes large distances between examples in the
same class, while the second term penalizes small distances between examples
with different class labels.
6. Decision Tree Classification (DTC) The DTC algorithm applies a divide
and conquer approach, resulting in an iterative process that starts by analyzing
each feature from the training data. It calculates the information gain for
each feature with respect to the possible class outcomes present in the training
data [55]. The C4.5 DTC algorithm implemented in the Weka 3.6.6 software [61]
(University of Waikato, Hamilton, New Zealand) was used here to analyze the
data.
7. Random Forest Random forest is an ensemble learning method for classifica-
tion and regression using multiple decision tree models. Each model is built with
a different subset of the same training data, with replacement. The remaining
training data are used to estimate error and to determine the importance of
each variable. We used the Random Forest algorithm implemented in the Weka
3.6.6 software [61] (University of Waikato, Hamilton, New Zealand) to classify
the data.
4.3.2 High-dimensional Microarray Data Sets
Fourteen publicly available microarray data sets in Table 4.1 were used to evaluate
our KITML approach. These data sets were obtained using two microarray technolo-
gies: single-channel Affymetric chips (6 sets) and double-channel cDNA chips (8 sets).
For each data set, the total number of samples, number of features, number of classes,
number of samples in each class, type of microarray chip, and tissue type are pro-
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Table 4.1: Sample-level cancer tissue classification data set description
Dataset Total Num of Num of Num of Samples Tissue
Name Samples Features Classes in Each Class
Alizadeh [78] 42 1095 2 21, 21 Blood
Bittner [79] 38 2201 2 19, 19 Skin
Bredel [80] 50 1739 3 31, 14, 5 Brain
Garber [81] 66 4553 4 17, 40,4, 5 Lung
Golub-v1 [82] 72 1877 2 47, 25 Bone marrow
Golub-v2 [82] 72 1877 3 38, 9, 25 Bone marrow
Gordon [83] 181 1626 2 31, 150 Lung
Nutt [84] 28 1070 2 14,14 Brain
Pomeroy [85] 42 1379 5 10, 10, 10, 4, 8 Brain
Su [86] 174 1571 10 26, 8, 26, 23,12, 11, 7, 27, 6, 28 Multi-tissue
Tomlins-v1 [87] 104 2315 5 27, 20, 32, 13, 12 Prostate
Tomlins-v2 [87] 92 1288 4 27, 20, 32, 13 Prostate
Yeoh-v1 [88] 248 2526 2 43, 205 Bone marrow
Yeoh-v2 [88] 248 2526 6 15, 27, 64, 20, 79, 43 Bone marrow
vided in Table 4.1. The 14 data sets had 2-10 distinct classes, 28-248 samples, and
1095-4553 features. These data sets have been used for clustering analysis in previous
studies [76, 77]. The clustering algorithms that have been applied to these data sets
are k-means clustering, mixture model clustering, spectral clustering, etc.. Most of
these data sets have not been explored for classification purposes, so we applied differ-
ent classification algorithms to these 14 data sets. The results presented in this thesis
are not comparable with analyses provides in the past studies since their analyses
used clustering algorithms and our’s used supervised classification algorithms.
4.3.3 Evaluation Setup
The experimental setup was designed to obtain reliable performance estimates
and avoid over-fitting, we used two loops. The inner loop was used to determine
the best parameters of the classifier using cross-validation sets. The outer loop was
used to estimate the performance of the classifiers built using the parameters found
by the inner loop. The test data sets used in the outer loop were independent from
the cross-validation sets. The outer loop uses a 10-fold cross-validation and the inner
loop uses a 4-fold cross-validation. We ran each of the 14 data sets through both
our KITML and the six test algorithms five(5) times and averaged the classification
results.
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4.3.4 KITML Setting
To construct constrained pairs, we consider the pairs of samples in the same class
to be similar and pairs of samples in different classes to be dissimilar. A total of
20C2 constrained pairs were randomly chosen in the learning process, where C is the
number of classes in each data set. The lower and upper bounds of the right hand
side of the constraints (l and u) in equation 4.5 are the 5th and 95th percentiles of the
observed distribution of distances between pairs of samples within each data set.
4.3.5 Performance Metrics
We used two classification performance metrics. The first is accuracy, which is
easy to interpret and simplifies statistical testing. Accuracy is defined as Acc =
TP+TN
TP+TN+FP+FN
, where TP is the total number of true positives, TN is the total num-
ber of true negatives, FP is the total number of false positives, and FN is the total
number of false negatives. Accuracy is sensitive to the prior class probabilities but
does not fully describe the actual difficulty of the decision problem for highly unbal-
anced distributions [16]. The second metric is macro-averaged F1 (F-measure). The
F-measure is a weighted combination of precision and recall. Precision is defined as
the ratio of the number of relevant records retrieved to the total number of irrelevant
and relevant records retrieved [89]. Recall is defined as the ratio of the number of
relevant records retrieved to the total number of relevant records in the data set [89].
F-measure is defined as:
F =
(β2 + 1)PmacroRmacro
β2Pmacro +Rmacro
, (4.10)
where β is typically set to 1. The multi-class precision and recall is define as:
Pmacro =
1
|C|
|C|∑
i=1
TPi
TPi + FPi
, (4.11)
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Rmacro =
1
|C|
|C|∑
i=1
TPi
TPi + FNi
, (4.12)
where TPi is the number of true positives for class i, FPi is the number of false
positives for class i, FNi is the number of false negatives for class i, and C is the
class.
4.3.6 Statistical Comparison among Classifiers
Statistical comparison is used to verify that the differences in accuracy between
algorithms are non-random. Since we have only 14 datasets we cannot assume that
the difference between results are normally distributed [90]. For this reason, we have
used the Wilcoxon signed-ranks test [91], which is a non-parametric alternative to
paired t-test. The Wilcoxon signed-ranks test ranks the difference in performance
of two classifiers for each data set, ignoring the signs, and compares the ranks for
positive and negative differences.
Let N be the number of pairs, x1,i and x2,i are the pairs of observation where
i = 1, 2, . . . , N . The Wilcoxon signed-ranks test works as follows.
1. The null hypothesis H0 is that the median difference between pairs of observa-
tion is zero. The alternative hypothesis H1 is that the median difference is not
zero.
2. The absolute values of the differences between pairs of observations |x1,i − x2,i|
and |sgn(x1,i − x2,i)| are calculated, where sgn is the sign function.
3. The smallest absolute difference pair gets a rank of 1, then next larger difference
pair gets a rank of 2, etc. The pairs with zero difference are excluded from the
test. The pairs with the same difference receive a rank as the average of the
ranks they span.
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4. The test statistic W is denoted as
W = |
Nr∑
i=1
sgn(x1,i − x2,i)Ri|, (4.13)
where Nr is the remaining pairs excludes zero difference pairs, and Ri is the
rank.
5. For Nr ≥ 10, since the sampling distribution of W coverages to a normal dis-
tribution, a z-score can be calculated as z = W−0.5
δw
, δw =
√
Nr(Nr+1)(2Nr+1)
6
. If
z > zcritical, we reject H0.
6. For Nr < 10, W is compared to a critical value from a reference table, if
W > Wcritical, we reject H0.
4.4 Group-level Severity/Stage Estimation with Set-ranking KITML
Another important task for molecular profiling based cancer diagnosis is the abil-
ity to further quantify/classify samples like blood or tumor samples into subtypes
which have distinct biomedical properties and result in varied prognoses. For in-
stance, samples of “blood cancers” –Diffuse Large B-Cell Lymphomas (DLBCLs)–
are indistinguishable based on histological methods yet are clinically heterogeneous.
Some patients respond well and exhibit prolonged survival while some do not [92].
It has been shown that using expression profiling techniques to stratify DLBCLs to
two subtypes is necessary for better classification [92]. For most cases of disease
severity/stage estimation in practice, the reference data normally include only posi-
tive (e.g., most severe disease state) and negative controls (e.g., least severe disease
state). The reason is that in many experiments using a blood assay or in clinical trials
only positive and negative controls were labeled to verify the success of the studied
techniques.
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It may be advantageous to design more advanced computational methods for cate-
gorizing the subtypes of cancer samples through molecular expression representation.
Here we propose a set-based ranking method using metrics learned from KITML for
severity estimation. Normally given a data set with multiple sample groups associated
with different severity levels of a type of cancer, we assume that the severity levels of
the control groups are known; the severity levels of the remaining sample groups are
unknown. The goal is to estimate the severity levels of these unknown sample groups
based on their relationship to the known control groups.
The basic idea of set-based KITML is to maximize the distances between dissim-
ilar sample groups, and minimize the distances between samples in the same group
or among similar groups. Specifically, the learned metric based on positive control
and negative control should give a maximum distance d(E+, E−) between these two
controls. The distances, between a sample group E? with unknown severity level
and two controls, can then be measured using this learned distance. These distances
should be proportional to d(E+, E−) and can be combined to locate the position of
the unknown sample group between the two controls, where the position indicates
the severity level.
Under the high-dimensional setting, using the parameter T learned through equa-
tion 4.8, we can calculate the distance measure between any data samples. Therefore,
we define and calculate distances between an unknown severity sample x?i (within E
?)
to E+, and to E−. The distance between x?i and E
+ is defined as
dA(x
?
i ,E
+) = (
∑
xk∈E+
x+k
|E+| − x
?
i )
T (I +XTXT )(
∑
xk∈E+
x+k
|E+| − x
?
i ). (4.14)
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Similarly, the distance between x?i and E
− is defined as
dA(x
?
i ,E
−) = (
∑
xk∈E−
x−k
|E−| − x
?
i )
T (I +XTXT )(
∑
xk∈E−
x−k
|E−| − x
?
i ). (4.15)
These two distances are then used to determine the predicted severity level y?xi of
x?i (equation 4.16), which indicate the predicted severity level is the ratio between the
distance of x?i to negative control and the distance of x
?
i to positive control. When
y?xi is close to 0, the severity of x
?
i is similar to that of the negative controls. On the
other hand, if y?xi is close to 1, the severity of x
?
i is similar to that of the positive
controls.
y?xi =
dA(x
?
i ,E
−)
(dA(x?i ,E
+) + dA(x?i ,E
−))
. (4.16)
The severity y? of E? is then defined as
y? =
∑
x?i∈E?
y?xi
|E?| . (4.17)
4.4.1 High-dimensional Molecular Profiling Data Data Sets
We used three microarray datasets from bladder, prostate and ovarian multi-
stage cancer patient studies (Table 4.2) [93]. (1) The bladder dataset contains gene
expression data of human bladder tumor samples from a clinical specimen bank.
There are 20 Ta (stage 1) samples, 11 T1 (stage 2) samples and 9 T2+ (stage 3)
samples, which contain a total of 7129 genes. After pre-processing according to [93],
we removed genes having missing data, leaving 3036 genes for our analysis. (2) The
prostate cancer data set was created in an attempt to characterize gene expression
profiles of specific Gleason patterns. The dataset contains gene expression data of 11
Gleason pattern three (stage 1) samples, 12 Gleason pattern four (stage 2) samples
and 8 Gleason pattern five (stage 3) samples. After removing the data with missing
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Table 4.2: Estimating severity of sample subgroups data set description
Dataset Total Num of Num of Features Staging Num of Sample
Name Samples Features after Pre-processing in Each Stage
Bjladder [95] 40 7129 3036 Ta, T1, T2+ 20, 11, 9
Prostate [96] 31 15488 9491 Gleason patterns 3,4,5 11, 12, 9
Ovary [94] 37 22283 18091 T1, T2, T3 18,5,14
values, 9491 genes were left for analysis. (3) The ovary data set is from genetically
engineered mouse models which are used to demonstrate the mutations of certain
signaling pathways in woman and mouse ovarian endometriod adenocarcinomas [94].
There are 18 T1 (stage 1) samples, 5 T2 (stage 2) samples and 14 T3 (stage 3)
samples. After pre-processing, 18091 genes were left for our analysis.
4.4.2 KITML Setting
Since there are 3 stages in each data set, around 75% of the stage 1 samples
are used as negative control E− and around 75% of the stage 3 samples are used as
positive control E+. These controls are used to learn distance metric. The remaining
25% of both stage 1 samples E?1 and stage 3 samples E
?
3, and all of the stage 2
samples E?2, are then used as test groups to evaluate the learned metric. This process
was repeated 4 times and averaged. For all three data sets, the constrained sample
pairs used were formulated by the samples within negative controls E− and positive
controls E+. The lower and upper bounds of the right hand side of the constraint (l
and u) in equation 4.5 are the 5th and 95th percentiles of the observed distribution of
distances between pairs of samples within each data set.
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5. Distance Measures Application Results and Discussion
5.1 Binary Severity Detection Results
The results obtained using three binary severity estimation approaches we have
studied(Chapter 2) – Hierarchical Clustering Analysis (HCA), Principal Component
Analysis (PCA) followed by K-means clustering and Decision Tree Classification
(DTC) – are consistent in distinguishing the severity of CRS between Anti-CD28
SA from that of other mAbs.
5.1.1 Hierarchical Clustering Analysis
Hierarchical Cluster Analysis was applied to the data shown in Table 2.4 and
Table 2.5. The resulting dendrograms are shown in Figure 5.1 and Figure 5.2. The
dendrograms represent the cluster hierarchy of the dataset; the horizontal axis is the
standardized Euclidean distance between pairs of clusters. Both dengrograms show
that the distances between the Anti-CD28 SA cluster and all other mAbs clusters are
quite large, indicating that the average response for Anti-CD28 SA is very different
from that of the other mAbs. Figure 5.1 shows the HCA for Anti-CD28 SA and
controls only, indicating clear separation between the means of both sets of data.
Figure 5.2 shows the HCA for Anti-CD28 SA, the controls, and the 6 mAbs from
the “Safe” class. Again, we see clear separation between Anti-CD28 SA and the
other treatments. In addition, the dendrogram in Figure 5.2 appears to separate the
controls and mAbs in the “Safe” class into two separate clusters with Tocilizumab,
IL-5, Palivizumab, CD22, and CD80 in one cluster and PBS, AutoPlasma and IL-1β
in the other cluster. However, the method does not provide direct explanation as to
why these treatments from the “Safe” class form two separate clusters and how the
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treatments within each cluster are related.
Figure 5.1: HCA dendrogram for Anti-CD28 SA, AutoPlasma and PBS
5.1.2 Principal Components Analysis (PCA) with K-means Clustering
Principal Components Analysis (PCA) was applied in order to reveal the internal
structure of the data in a way that best explains the variance in the data. It is well
documented that in order to be successful, the attributes subject to PCA need to have
similar dynamic ranges [54, 58]. However, the attributes from our dataset have a large
variation in their dynamic ranges, as shown in column 4 of Table 2.1. As shown in
Figure 5.3, our attributes also exhibit a nearly linear relationship between the mean
and the standard deviation for samples of different treatments. This property allows
us to reduce the differences in the dynamic ranges of the attributes by using the
logarithmic transformation [58, 59, 60]. This transformation replaces each sample
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Figure 5.2: HCA dendrogram for all the treatments
data value by its logarithm (base 10) before applying PCA.
We applied PCA to the samples from Anti-CD28 SA and the controls in Table 2.4
and sorted the Principal Components in descending order by the amount of variance
associated with them. The variances associated with each of the Principal Compo-
nents are listed in Table 5.1, where we see that the first three Principal Components
account for more than 90% of the variance of the data. This observation suggests that
we can possibly ignore the rest of the principal components, with little impact on the
underlying structure of the data. We then represented the data graphically using a
three-dimensional scatter plot against the three principle components (Figure 5.4(a)).
Principal Components Analysis (PCA) helps with visualizing but does not cluster
the data points in the new coordinate system. In order to identify sample populations
in the new attribute space, we used K-means clustering. The technique requires that
we specify the number of clusters into which observations will be assigned before the
clustering process starts. We used the previous HCA to determine the number of
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Figure 5.3: Standard deviation vs. means for all cytokines showing the least squares
linear approximation for all points (IFN-γ, IL-4 and IL-17 were plotted with and
without Anti-CD28 SA to confirm the linear relationships)
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Figure 5.4: (a) Graphical representation of the data using the first three principal
components of PCA (b) K-means clustering results based on the first three principal
components (c) Visual representation of the data using the known labels to identify
populations after applying PCA (d) K-means clustering showing misclassified samples
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clusters, which in this case is 3. Figure 5.4(b) shows the samples corresponding to
each cluster in different colors, and Table 5.2 shows the number of samples in each
cluster and the label associated with them. It is notable that Cluster 1 consists mostly
of Anti-CD28 SA samples. Clusters 2 and 3 are dominated by AutoPlasma and PBS
samples, respectively. These results confirm that samples from Anti-CD28 SA and
the two controls can be separated from each other using this method.
Table 5.1: Variance associated with principal components for Anti-CD28 SA, PBS
and AutoPlasma
Variance included in 11 Principal Components (PC)
PC 1 PC 2 PC 3 PC 4-11
77.60% 10.90% 3.10% 8.40%
91.60% 8.40%
Table 5.2: The number of samples for each treatment in each cluster found by K-
means clustering on the data using the first three principal components
CD28 AutoPlasma PBS
Cluster 1 132 10 0
Cluster 2 20 142 5
Cluster 3 0 0 75
Applying the known class labels of the samples to visualize the data as shown
in Figure 5.4(c), we see that each sample population, Anti-CD28 SA and the two
controls, is located in a different region within the three-dimensional space. Using
PCA we are thus able to graphically represent the differences in the cytokine responses
for each sample, and can observe how samples from a given population are grouped
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in a specific region. These observations are consistent with the dendrogram from
Figure 5.1 in which the differences between the mean response of Anti-CD28 SA and
the controls are highlighted. Using PCA we can not only corroborate this separation,
but also see the differences between samples. Finally, using the information from the
labels associated with each sample and the results obtained from K-means clustering,
we can identify and visualize the misclassified samples. Figure 5.4(d) shows the
misclassified samples. Not surprisingly, they are located on the boundaries of the
established cluster.
Next, we repeated the analysis (PCA with K-means clustering) using the samples
from all treatments shown in Table 2.5. This analysis would attempt to classify all
treatment samples, not just the Anti-CD28 SA, AutoPlasma, PBS sample set. The
variances associated with each of the Principal Components are listed in Table 5.3.
Again, the first three principal components accounted for more than 90% of the
variance of the data; we used these three principal components to create a three-
dimensional scatter plot of the samples from Anti-CD28 SA, “Safe” treatments, and
controls (Figure 5.5(a)).
Table 5.3: Variance associated with principal components for all treatments
Variance included in 11 Principal Components (PC)
PC 1 PC 2 PC 3 PC 4-11
75.20% 11.90% 3.20% 9.70%
90.30% 9.70%
After applying PCA, we applied K-means clustering to the results of PCA, con-
sidering the first three Principal Components. As before, we used HCA to guide us as
to the number of clusters. The dendrogram in Figure 5.2 suggested 3 clusters, which
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we have used to run K-means clustering on the transformed data. The clustering re-
sults are shown in Figure 5.5(b) and are detailed further in the Table 5.4. The table
shows the three clusters and their constituents. The first cluster consists mostly of
Anti-CD28 samples; the second cluster consists mostly of samples from AutoPlasma,
and the third cluster consists mostly of samples from PBS.
Table 5.4: The number of samples for each treatment in each cluster found by K-
means on the data using the first three principal components
CD28 AutoPlasma PBS CD80 CD22 IL-1 IL-5 Tocilizumab Palivizumab
Cluster 1 132 12 0 2 2 2 4 0 0
Cluster 2 20 140 4 6 6 0 4 8 8
Cluster 3 0 0 76 0 0 6 0 0 0
The samples from CD28 and the two controls (AutoPlasma and PBS) can again be
distinguished from one another using this technique. Most samples from the “Safe”
treatments are clustered with the controls, indicating the relative similarity of re-
sponse between the controls and the safe treatments. The small number of the “Safe”
and control samples makes it impractical to cluster these samples separately. The
results of this analysis are consistent with the results from HCA and the observations
made on PCA with labeled data. When we use the known labels of the samples
to visualize the data after PCA is applied (as shown in Figure 5.5(c)), we see that
most of the samples from the “Safe” treatments were placed closer to the control
samples than to the Anti-CD28 SA samples. This observation is consistent with the
dendrogram obtained from the HCA analysis in Figure 5.2.
5.1.3 Decision Tree Classification (DTC)
Using HCA and PCA with K-means clustering we can automatically separate
samples from Anti-CD28 SA and other treatments, and visualize the data in a three-
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Figure 5.5: (a) Data (all treatments) representation based on principal components
after selecting the three first Principal Components (b) K-means clustering results
based on the first three principal components (c) Representation of the data based
on the labels known for each sample
61
dimensional space. However we still have not determined how the different cytokine
releases led to this separation. To add this dimension to the study, we have employed
Decision Tree Classification (DTC). The two training data sets described in Tables 2.4
and 2.5 were used to train the DTC algorithm. Training data set 1 included 136
samples in the “Safe” class and 80 samples in the “CD28” class, for a total of 216
samples (Table 2.4). The cytokine that best separated the two classes among the 11
measured cytokines was selected first by the DTC, and the selection process was then
repeated with the next best cytokine, etc. The tree model shown in Figure 5.6(a) was
built using training data set 1. As can be seen from the root node, the cytokine which
produced the first split of data was IFN-γ. The 131 samples in this data set with
values of IFN-γ ≤ 31.5pg/ml were classified into the “Safe” class while the 66 samples
in this data set with values of IFN-γ greater than 136.9pg/ml were classified into the
“CD28” class. Samples with values of IFN-γ between 31.5pg/ml and 136.9pg/ml
required further analysis using the IL-2 node to identify the corresponding classes.
Values of IL-2 ≤ 28.1pg/ml were in the “CD28” class, and values of IL-2 greater than
28.1pg/ml were in the “Safe” class. On the left branch of IL-2 node, the notation
“(15/1)” indicates that of the 15 samples assigned to the “CD28” class, one (1) sample
was misclassified. The accuracy of this tree model in classifying new data correctly
is estimated by the cross validation procedure described in Chapter 2.7 (In addition,
10-fold cross validation was also used, and the results are discussed in Appendix A).
A square Confusion Matrix (CM) is used here to record the performance of the DTC
model. Each column of the CM represents the instances of the predicted class. Each
row represents the instances of the actual class. CMijis the number of samples in
the true class i which were assigned to predicted class j. Ideally CM is a diagonal
matrix.
Cross validation was performed 100 times. The average accuracy after 100 times
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was 95.5%; the corresponding Confusion matrix is shown in Figure 5.6(b). The false
alarm or false positive rate of the DTC model was 5.1% and the misdetection or false
negative rate was 3.8%. The classification accuracy obtained from the cross validation
method is high, indicating that the developed model was reliable in this case in terms
of its ability to classify samples from unknown donors.
Figure 5.6: (a) Decision Tree model using training data set 1 with 11 cytokines (b)
The confusion matrix shows the performance of the cross validation
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Training data set 2 included 184 samples from the “Safe” class and 80 samples
from the “CD28” class, for a total of 264 samples (Table 2.5). The tree model and its
Confusion Matrix are shown in Figure 5.7. The average accuracy of the classification
for this tree model was 93.1% for 100 iterations of the random donor splitting method.
The Confusion Matrix is shown in Figure 5.7 (b). The classification rules can be
inferred from the model in the same manner as for training data set 1. Here we see
that IL-17, IL-10 and TNF-α (monomeric) are used in addition to IFN-γ and IL-2 to
classify the samples.
The DTC model generated using training data set 2 is shown in Figure 5.7(a),
where we observe that the root node was IFN-γ. It produced the first data split
identifying 164 samples in the “Safe” class with values of IFN-γ ≤34.1pg/ml and 100
samples with values of IFN-γ ≤34.1pg/ml that required further classification. The
cytokine IL-17 was used as the second cytokine for separation, suggesting that it is
relevant for classification, although IL-17 release is not commonly measured in CRS
assays (e.g., [56][72]).
Both DTC models identified IFN-γ as the most relevant cytokine for classification.
Next, we have removed IFN-γ samples from the dataset, and ran our models with
the remaining 10 cytokines. The results are shown in Figure 5.8, where both models
identify IL-17 as the root node. The resulting tree structures are more complex
than the previous analysis with IFN-γ as the root node; however, the classification
accuracies are still relatively high at 90.7% and 95.1% for training datasets 1 and 2,
respectively. These results indicate that IL-17 may also be relevant for classification
of these cytokine data.
In order to assess the ability of the DTC models (shown in Figure 5.6(a) and
Figure 5.7(a)) to analyze new data, we used test sets for the models that did not in-
cluded any of the data in the training set. Specifically, we used the (hitherto unseen)
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Figure 5.7: (a) Decision Tree model using training data set 2 with 11 cytokines (b)The
confusion matrix shows the performance of the cross validation
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Figure 5.8: In order to verify the importance of IL-17, IFN-γ has been removed from
training data set 1 and 2. DTC was applied to the remaining 10 cytokines and the
two tree models are: (a) Tree model corresponding to training data set 1 (b) Tree
model corresponding to training data set 2. Both two tree models show IL-17 as the
root node.
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test data described in Table 2.6. The accuracy of the two models in Figure 5.6(a)
and Figure 5.7(a) are provided in Table 5.5 and Table 5.6, respectively. The accu-
racy percentages are 92.9% for the DTC in Figure 5.6(a) and 93.7% for the DTC in
Figure 5.7(a).
Table 5.5: Test results for the tree model in Figure 5.6(a)
Classifier Outcome Test accuracy (92.9%)
Safe CD28
Known Safe 63 9 False alarm/False positive 12.5%
CD28 0 54 Misdetection/False negative 0%
Table 5.6: Test results for the tree model in Figure 5.7(a)
Classifier Outcome Test accuracy (92.9%)
Safe CD28
Known Safe 72 0 False alarm/False positive 12.5%
CD28 8 46 Misdetection/False negative 0%
5.1.4 Discussion
The results obtained from the analysis of our dataset, using the three machine
learning approaches, are consistent in discriminating between Anti-CD28 SA and
other mAbs with respect to CRS. However, each approach provides different infor-
mation about the studied data set.
HCA highlights the differences between the treatments using the means of their
cytokine response. It also provides a simple cluster hierarchy of the treatments, e.g.,
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in Figure 5.2 we identified three clusters corresponding to Anti-CD28 SA, controls,
and the other treatments in the “Safe” class. These findings are consistent with the
results from Walker et al. [18] and give guidance on how many clusters may exist in
the data. On the other hand, HCA does not allow classification of individual samples
from the dataset since it uses the average response for each mAb as the basis for the
measure of “distance” in order to find the cluster hierarchy. Using HCA it is not clear
whether some cytokines have more discriminatory relevance than others.
PCA was used in this study to build scatter plots to visualize the data sample-by-
sample. The first three principal components that account for most of the variance
were used to visualize the data, showing where each sample is located in the suggested
principal components space. We used K-means clustering to further analyze the PCA
results1 seeking three clusters, which was suggested by HCA. Samples from Anti-CD28
SA were placed far away from the other samples, and samples from the treatments in
the “Safe” class were closer to PBS and AutoPlasma than they were to Anti-CD28
SA. However, PCA and K-means clustering provided, in addition to the information
provided by HCA, a method of clustering actual samples rather than clustering the
means of samples. The resulting classification can also be used to assign unlabeled
samples to a particular cluster, based on the distance of the sample from the centroid
of the cluster. The principal components used in this approach do not have a direct
biological interpretation.
DTC fills this biological interpretation gap. As with HCA and PCA, DTC can
also distinguish Anti-CD28 SA from all other treatments and controls, but in addition
it provides information about which cytokines are most relevant to the separating of
1We applied K-means clustering to both raw data and the outcomes of PCA on the raw data.
The clustering error rates were comparable (8%-10% on average in both cases). However, using
PCA gave a clear low-dimensional representation of the data. Furthermore, we could visualize the
results of K-means clustering using the 3 principal components from PCA, which could not be done
directly using the 11-dimensional raw data.
68
Anti-CD28 SA. The rules created by DTC specified thresholds that separated cytokine
release levels into groups. These groups can then be associated with the “Safe” and
the “CD28” classes. For example, in the DTC model in Figure 5.6(a), when the
value of IFN-γ is greater than 136.9pg/ml, the model classifies 66 samples into the
“CD28” class. The value “136.9pg/ml” is a threshold chosen by iteratively calculating
information gains for threshold candidates associated with each cytokine and using
the value with the highest information gain (in [62], Section 6.1).
In addition to ease of interpretation, DTC shows other advantages in analyzing bi-
ological data. First, once the tree model is constructed from a training data set, it can
easily be used to classify unknown samples as we demonstrated using the test data set
in Table 2.6. Our results also show that DTC provided high classification accuracy,
and required relatively little effort from users for data preparation. Similarity conclu-
sions were reported in [97], which compared several machine learning algorithms in
cancer tissue classification , and in [98], which studied the use of Decision Tree based
classification of uncertain data.
Our study needs to be viewed in the context of several other investigations of
cytokine release through machine learning approaches [29, 99, 100, 101, 102, 103,
104, 105]. Collectively these studies point to the usefulness of applying the three ma-
chine learning approaches studied here (HCA, PCA, K-means clustering and DTC)
to mAb induced cytokine release data from a variety of assays and conditions. In
order to apply these approaches to a new assay, the following requirements should
be met. First, there should be some labeled reference data from mAbs with known
CRS potential. In some cases we may know the CRS potential of all the mAb and
controls. In other cases, when new mAbs with unknown CRS potential are studied,
we could measure their similarity to the known mAbs or controls to infer the CRS
potential of the new mAbs. Second, enough samples should be collected to get useful
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and consistent results. This has been done, in our case, by starting with a “reason-
able” number of samples (5-10), categorizing the samples using the machine learning
approaches, then repeating with about ten more samples each time. Once the results
started stabilizing (which in our case was at about 120 samples), we concluded that
enough samples have been used (see Appendix D).
Prior studies have shown that CRS is mainly related to high levels of IFN-γ, TNF-
α, IL-6, IL-2, IL-8, and IL-10 [56][72]. The analysis of TGN 1412 treated patients
shows that TNF-α was increased at 1 hour after infusion and IFN-γ, IL-2, IL-6 and
IL-10 were increased after 4 hours [106]. In addition, recent work using mathematical
modeling suggests that there is a cause and effect relationship among some of the
cytokines [107]. Serum collected from the TGN 1412 trial showed that INF-γ and
TNF-α are the first cytokines to be produced and from the mathematical modeling
INF-γ is thought to subsequently induce IL-10 and IL-6, whereas, TNF-γ is thought
to induce IL-8 and IL-10. In fact, our DTC models identified IFN-γ, TNF–α and
IL-10 as important cytokines in CRS, corroborating these findings.
Our DTC analysis suggested IL-17 as a potentially important cytokine in classi-
fying treatments as “Safe” class or “CD28” class. IL-17 has not been identified so far
in the literature as an important cytokine in the context of CRS. Literature reports
of cytokine analysis of the TGN 1412 trial did not measure IL-17. In the published
literature, this cytokine has not been measured in assays developed for detecting
mAb-induced CRS. Since IL-17 is a pro-inflammatory cytokine, it should contribute
to CRS since it has been shown to stimulate a highly pro-inflammatory gene signa-
ture [108]. It induces NF-Kβ [109], a transcription factor historically known for fast-
acting pro-inflammatory cellular responses [110]. IL-17 is also known to induce IL-6,
IL-8, G-CSF, and prostaglandin E2 production by mesenchymal cells and cause accu-
mulation of neutrophils in the blood and tissues [111]. This IL-6 production could act
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on acute phase proteins and lead to inflammation. Moreover, IL-17 has been shown
to increase the effects of TNF-α partially by increasing Tumor Necrosis Factor Re-
ceptor 2 (TNFR2) or Lipopolysaccharide-Induced CXC Chemokine (LIX) [111, 112],
possibly contributing to the CRS cascade, which is thought to start with TNF-α and
IFN-γ. IL-17 is thought to be important in chronic inflammatory conditions such as
autoimmune diseases, transplantation, and infections [113, 114]. In addition to IL-
17 being pro-inflammatory in nature, IL-17 has been shown to be involved in other
forms of cytokine storm including those induced by bacteria and transplant [115, 116].
Therefore, it is not surprising that our DTC model was able to identify IL-17 as an
important cytokine in detecting CRS even though this correlation has not been noted
so far in the literature.
To conclude, we used different approaches to analyze data from an in vitro assay
that uses human blood to assess the potential of CRS from different mAbs. All of the
approaches were able to identify the treatment that caused the most severe cytokine
response. Additionally, PCA and K-means clustering allowed classifying treatments
sample by sample and visualizing them in a low dimensional space. DTC models
showed the relative importance of various cytokines such as IFN-γ, TNF-α and IL-10
to CRS. The combined use of the techniques provided a more comprehensive view of
the data and better-informed processes for selection of parameters and thresholds.
5.2 Severity Estimation using Distance Metric Learning Results
5.2.1 Cytokine Release Syndrome Data Set Results
The analyses of Cytokine Release Syndrome (CRS) data set by Severity Estima-
tion using Distance Metric Learning (SE-DML) have two steps: (1) group severity
level estimation; (2) individual severity level estimation.
The three groups – safe(E?1), middle(E
?
2) and severe(E
?
3) listed in Table 3.2 – are
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tested using the distance metric learned from positive controls (E+: Anti-CD28 SA
and LPS) and negative controls (E−: PBS and AutoPlasma). The severity level of
each group estimated by SE-DML is a normalized value between 0 and 1 showing in
Table 5.7. These levels have an order of y1 < y2 < y3, indicating that these levels
matched their group labels. These results illustrate that the SE-DML approach can
correctly estimate the severity of the treatment groups.
Table 5.7: Severity levels for three treatment groups in CRS data set
Class Severity level yi
Safe (E?1) 0.081±0.0143
Middle (E?2) 0.121±0.0257
Severe (E?3) 0.482± 0.1106
The 26 treatments listed in Table 3.2 are also estimated using the distance metric
learned from positive controls (E+: Anti-CD28 SA and LPS) and negative controls
(E−: PBS and AutoPlasma). The ideal results would be the 8 treatments in the
severe group have higher values than that of the treatments in the other two groups.
All the 6 treatments in the middle group have severity levels right in between that
of the treatments in the other two treatments. The 11 treatments in the safe group
have the lowest severity levels. But the real results are much more complex than the
ideal condition. Several treatments have severity levels mixed with treatments within
other groups. The severity levels of the 26 treatments shown in Figure 5.9 are sorted
in a descending order from the top to the bottom, with higher treatments indicating
more severe CRS reactions. Almost all the treatments in the severe group have a
higher severity level than treatments in the other two groups except CD40, which
stays in the middle of Figure 5.9. Two safe treatments, IL-6, and CD80 and one from
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the middle class (Anti-VEGF) are mixed with treatments in the severe group. The
middle group treatments are mostly mixed with safe treatments but have relative
higher severity levels than safe treatments.
Figure 5.9: Severity levels of 26 test treatments in CRS data set. The standard
deviation of the estimation is shown as error bar in the figure. Red treatments are in
severe-CRS group, green treatments are in middle group and blue treatments are in
safe class.
5.2.2 Cardiotocography Data Results
Based on the data set described in Chapter 3.7, the learned A matrix is a 21
by 21 positive definite matrix. The severity levels over 10 iterations are shown in
Table 5.8. They indicate that the severity level of E?1 is almost the same as the
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negative control E− and the severity level of E?3 is very close to the positive control
E+. The severity levels of E?1 and E
?
3 illustrate that the proposed approach works
here because E?1 and E
− are from the same class in the CTG data set, as well as E?3
and E+. Moreover, without any prior information about E?2, the proposed approach
still ranked the severity of E?2 to the right position – between E
?
1 and E
?
3.
Table 5.8: Average severity levels of three classes in test data and their standard
deviations over 10 fold cross validation
Class Severity levels yi
Normal (E?1) 0.003±0.002
Suspect (E?2) 0.251±0.058
Pathologic (E?3) 0.905±0.070
5.2.3 Quantitative Structure Activity Relationship (QSAR) Results
Based on the data set described in Chapter 3.8, the learned A matrices are (1) a 27
by 27 positive definite matrix and (2) a 60 by 60 positive definite matrix respectively
according to the different number of attributes. The average severity levels of the two
data sets over 20 times are shown in Table 5.9. In both data sets, E?1 is the closest to
E− and it has the lowest severity level among the three sample groups; E?3 is the closest
to E+ and it has the highest severity level among the sample groups; The severity
levels of E− falls right in between the other two sample groups. These severity levels
indicate that with only two extreme sample groups, the SE-DML approach was able
to rank the severity of three middle sample groups correctly in this case.
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Table 5.9: Average severity levels of test data in the two QSARs data sets and their
standard deviations
Sample Group Severity levels yi of Pyrimidines Severity levels yi of Triazines
E?1 0.134± 0.063 0.720±0.123
E?2 0.437± 0.193 0.755±0.096
E?3 0.659± 0.220 0.902±0.044
5.2.4 Algorithm Comparison
The estimated severity levels of the four data sets by the 5 approaches are shown
in Figure 5.10. The four bar charts (row-wise) represent results of the four data sets.
In each chart, there are five sets of bars representing the severity levels (y1, y2 and
y3) of the three test groups E
?
1, E
?
2 and E
?
3 estimated by the 5 approaches. The blue
bar is the severity level y1 of E
?
1, the green bar is the severity levels y2 of E
?
2, and the
red bar is the severity levels y3 of E
?
3. Each yi is the mean of sample severity levels
within E?i . The standard deviation is shown as the error bar in the figure.
For each set of bars, we ignore the absolute difference between y1, y2 and y3 but
only evaluate relative order of these three severity levels. We consider the relative
order of y1 < y2 < y3 as the correct severity estimation since it matches the true
group label. For CRS data set, only SE-DML can correctly estimate the relative
order among the severity levels of the three test groups. For CTG data set, all the 5
approaches correctly estimate the relative ordering. For Pyrimidines data set, linear
regression fails to distinguish the severity levels of E?1 and E
?
2 and the results show a
large standard deviation, indicating it can not estimate the severity of Pyrimidines
data set robustly. For Triazines data set, the SE-DML approach is the only one that
can identify correctly the relative order of y1 < y2 < y3.
According to the relative orders among the predicted group-level severity levels,
our SE-DML approach has achieved the best performance among all the 5 approaches.
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Figure 5.10: Severity estimation results of the 5 approaches on four data sets. Each
bar chart presents the estimated severity levels of one data set.
However, this approach could not capture the sample-level severity estimation since
only using average severity level representing a group of samples may not be suffi-
cient enough to illustrate the effectiveness of SE-DML approach. We need to evaluate
how well the individual sample’s severity level matches to other samples within this
sample’s group. Silhouette coefficients provide a numerical measure about this evalu-
ation. For each data set, there are three test groups giving three clusters of individual
sample’s severity levels. Higher silhouette coefficient of a sample indicates its severity
level is well-matched to its own group, when compared to severity levels of samples in
other groups. The average silhouette coefficient of the 5 approaches for four data sets
are listed in Table 5.10. The bold number in each row indicates the best silhouette
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coefficient of each data set. The SE-DML approach has the best silhouette coefficient
in 3 out of the 4 data sets.
Table 5.10: Silhouette coefficients of the 5 approaches
SE-DML SE-DML with
Euclidean
Distance
SE-DML
with
LMNN
Linear Re-
gression
Support
Vector
Regression
CRS -0.1114 -0.0821 -0.1376 -0.3654 -0.1015
CTG 0.7362 -0.0271 0.2987 0.2905 0.6657
Pyrimidines 0.1293 0.0063 0.0905 -0.0753 0.0116
Triazines 0.1186 -0.0135 0.0302 -0.2814 0.1128
5.3 High-dimensional Cancer Tissue Data Classification Results
5.3.1 Sample-level Cancer Tissue Classification Results
Cross Validation Accuracy of Variations of Neighbor Sizes in K-nearest
Neighbor (KNN) Classification
In KNN classification, nearest neighbor size k is a user-defined parameter and
the choice of k is very critical to the classification performance. The optimal value
of k is based on the cross validation accuracy of training samples. Generally, the
larger values of k reduce the effect of noise on the classification, but make boundaries
between classes less distinct [117]. Figure 5.11 shows the cross validation accuracy of
KNN KITML and KNN with Euclidean distance as a function of different neighbor
sizes (from k = 1 to 11) for all 14 data sets listed in Table 4.1. The purpose of this
analysis is finding the k value that leads to the highest classification accuracy for
training data. Then when testing KNN KITML and KNN with Euclidean distance,
this optimal value of k will be used in the classification. For example, for Alizadeh
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Figure 5.11: Comparing cross validation classification accuracy when varying neighbor
size k
data set, when k = 7 KNN KITML has the highest cross validation accuracy and
when k = 5 KNN with Euclidean distance has the highest cross validation accuracy.
Moreover, from Figure 5.11, we can see that the cross validation accuracy of KNN
KITML does not have an obvious trend when k is getting larger. For KNN with
Euclidean Distance, it can be seen that except Alizadel, Bitterner and Bredel data
sets, the cross validation accuracy decreases when k is getting larger. From all these,
we can see the importance of k in the performance of KNN algorithm.
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Overall Accuracy and Macro-average F1
The results of the algorithm comparison with accuracy and macro-average F1 as
the performance metrics are shown in Table 5.11 and Table 5.12, respectively. For
Bredel data set, the best accuracy is obtained by KNN KITML, which is 0.8760. In
contrast, the Macro-averaged F1 obtained by KNN KITML is 0.7707 where there is
an obvious performance decrease. This decrease can be explained by the difficulties
of this classification task – the Bredel data set has unbalanced classes. It has three
classes with the smallest class having a prior probability of only 10% (5 out of 50
samples). Similarity, Garber data set also has unbalance class distribution. The
KNN KITML results on Garber data set are 0.8121 for accuracy and 0.6118 for
macro-averaged F1. The reason is that Garber data set has an unbalanced class
distribution of {17, 40, 4, 5}.
Overall, the KNN KITML has the best average performance among all 8 clas-
sification algorithms for both accuracy and Macro-averaged F1. Specifically, KNN
KITML achieved best performance in accuracy in 9 out of 14 data sets (Table 5.11).
LMNN has better classification in Golub-v1, Nutt, Tomlins-v2 and Yeoh-v1 data sets.
For Golub-v2 data set, KNN KITML and LMNN achieved the same accuracy. KNN
ITML* achieve the best accuracy for Bittner data set. For Golub-v1 data set, KNN
ITML* and LMNN have the same best accuracy. KNN KITML also generated best
macro-average F1 in 9 out of 14 data sets (Table 5.12). For Nutt, Tomlins-v2 and
Yeoh-v1 data sets, LMNN outperformed KNN KITML in terms of Macro-averaged
F1. For Garber data set, Random Forest outperformed KNN KITML in terms of
Macro-averaged F1. KNN ITML* has the best Macro-averaged F1 for Bittner data
set.
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Wilcoxon Signed-Ranks Test Results
Wilcoxon signed-ranks test is used to verify that the differences in accuracy be-
tween algorithms are non-random. The Wilcoxon signed-ranks test ranks the dif-
ference in performance of two classifiers for each data set, ignoring the signs and
compares the ranks for positive and negative differences. The results of right-sided
Wilcoxon signed-ranks test are shown in Table 5.15. The p-values of the tests be-
tween KITML and the other 6 classification algorithms indicate that KNN KITML
achieved better performance than all the other algorithms in terms of accuracy and
macro-average F1 at 5% significance level.
Table 5.15: p-values of right-sided Wilcoxon signed-ranks test between KNN KITML
and the other 7 classification algorithms
KNN
ITML*
KNN Eu-
clidean
SVM Lin-
ear
SVM
RBF
DTC Random
Forest
LMNN
p-values for
accuracies
0.0012 6.1e-05 6.1e-05 6.1e-05 6.1e-05 6.1e-05 0.03
p-values
for macro-
averaged
F1
6.1e-04 6.1e-05 6.1e-05 6.1e-05 6.1e-05 1.8e-04 0.02
Time Complexity Analysis
The objective of the learning process in KITML is to learn the n by n parameter
matrix in the distance metric, where n is the number of samples. Therefore, for each
constraint (l or u) defined in equation 4.5, the time complexity is O(n2). For the entire
learning process looping through all the constraints, the time complexity is O(cn2),
where c is the number of constraints defined in Chapter 4.3.4. We further analyzed the
execution times for the two best classification algorithms – KNN KITML and LMNN.
Our experimental setup was designed to obtain reliable performance estimates and
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avoid over-fitting using two loops. The inner loop is used to determine the best
parameters of the classifier using cross-validation sets. The outer loop is used to
estimate the performance of the classifiers built using the parameters found by the
inner loop. In the execution time analysis, we only ran outer loop for each algorithms.
For the inner loop we usde default parameters for each algorithms. Figure 5.12 shows
the execution time analysis. KNN KITML requires much less time, taking 2-519
seconds to run each data set, while for LMNN this typically exceeded 24 hours to
finish calculation. All experiments were executed in Matlab R© 2012a software (The
Mathworks, Natick, MA) on a Quad core Intel 3.5GHz PC.
5.3.2 Estimating Severity of Sample Subgroups
The estimated severity levels as determined by KITML on the three microarray
datasets from bladder, prostate and ovarian multi-stage cancer patient studies (Ta-
ble 4.2) are shown in Figure 5.13. Each data set contains samples from 3 different
cancer stages, indicating 3 different severity levels. Each yi is the mean of sample
severity levels within E?i . The standard deviation is shown as the error bar in the fig-
ure. We consider the relative order of y1 < y2 < y3 as the correct severity estimation
since it matches the true group labels and our KITML approach correctly estimated
the relative ordering among the severity levels of the three test groups. Notably,
without any prior information about E?2 in each data set, the proposed approach still
can estimate the severity level y2 of E
?
2 in the right order – between y1 and y3.
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Figure 5.12: Comparing execution time between KNN KITML and LMNN for all 14
data sets. Since Garber, Golub-v1, Golub-v2, Gordon, Su, Tomlins-v1, Yeoh-v1 and
Yeoh-v2 need more than 24 hours execution time, we draw their bars using the same
longest length in the figure.
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Figure 5.13: Severity estimation results of three high-dimensional data sets. The blue
bar is the severity level y1 of test group E
?
1, the green bar is the severity levels y2 of
test group E?2, and the red bar is the severity levels y3 of test group E
?
3.
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6. Conclusions and Future Work
This thesis describes distance measures used to address two kinds of problems:
severity estimation and cancer tissue classification. For severity estimation, we first
applied several binary severity estimation approaches to Cytokine Release Syndrome
(CRS) data. These approaches were (i) Hierarchical Cluster Analysis (HCA); (ii)
Principal Component Analysis (PCA) followed by K-means clustering; and (iii) Deci-
sion Tree Classification (DTC). All three approaches were able to identify the treat-
ment that caused the most severe cytokine response. HCA was able to provide in-
formation about the expected number of clusters in the data. PCA coupled with
K-means clustering allowed classification of treatments sample by sample, and visu-
alizing clusters of treatments. DTC models showed the relative importance of various
cytokines such as IFN-γ, TNF-α and IL-10 to CRS. The use of these approaches in
tandem provided better selection of parameters for one method based on outcomes
from another, and an overall improved analysis of the data through complementary
approaches. Moreover, the DTC analysis showed in addition that IL-17 may be cor-
related with CRS reactions. This correlation has not yet been corroborated in the
literature.
Next we went beyond binary severity estimation using distance metric learning
algorithms which allowed us to determine a more graded severity level for different
bioinformatics areas. We use the known severity of both negative controls (least se-
vere) and positive controls (most severe) to define the range of possible severity, and
used this information to learn a distance metric from data. This learned metric is used
to measure the distances of an unknown disease or reaction from both the negative
controls and positive controls and thus to estimate its severity. We evaluated four
known data sets which studied the severity of CRS, the severity of fetal hypoxia, and
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toxic reactions of chemical compounds. We compared our approach to four public
methods from the literature. The results showed that our approach was able to esti-
mate correctly the severity of the disease/reaction better than the other approaches.
Regression based approaches and approaches that use other distance metrics were less
stable in estimating the corrected results. In the future, we would like to generalize
our severity estimation approaches to more data sets and test their ability to estimate
the severity in different bioinformatics areas. Currently, the learning distance metric
is based on positive and negative controls, however, it is possible that some samples of
middle severity are also known beforehand, we would like to incorporate these known
samples to improve our learned metric. How to revise the current severity estimation
framework to adapt this scenario is left for future work.
The second problem we addressed in this thesis is cancer tissue classification. We
used a Kernelized Information-Theoretic Metric Learning (KITML) approach that
optimizes a distance function to improve the classification of cancer microarray data
and scale to high dimensionality. By learning a nonlinear transformation in the input
space implicitly through kernelization, KITML permits efficient optimization, low
storage, and improved learning of distance metric. We proposed two applications of
KITML using high-dimensional microarray data. (1) For sample-level tissue classifi-
cation, the learned metric is used to improve the performance of k-nearest neighbor
classification. (2) For estimating the severity level or stage of a group of samples, we
propose a set-based scheme to identify the stage/severity of different cancer. For the
sample-level cancer classification task, we evaluated fourteen cancer gene microarray
data sets and compared with six other state-of-the-art approaches. The results show
that our approach achieves the best overall performance for the task of molecular
expression driven cancer tissue classification. For the group-level cancer stage es-
timation, we test the proposed set-KITML approach using three multi-stage cancer
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microarray data sets, and correctly estimated the stages of sample groups for all three
studies.
Currently we use the learned distance metric to estimate severity levels of differ-
ent biomedical conditions and to classify cancer tissue microarray data. However, the
use of learned distance metrics may not be limited to just these applications, e.g., in
cancer diagnosis, the learned metric may be used to find similar patient cases to a
target patient case using a nearest neighbor search. This may provide a great tool
for physicians when determining relevant prognoses or treatment plans. In addition,
there are many other possible distance metric learning algorithms, but we only com-
pared some of them. Future work may include a comprehensive comparison with
more distance metric learning algorithms to determine the best approach for a given
bioinformatics scenario.
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Appendix A. List of Abbreviations
Abbreviations Definition
CM Confusion Matrix
CRS Cytokine Release Syndrome
CTG Cardiotocography
DLBCLs Diffuse Large B-Cell Lymphomas
DTC Decision Tree Classification
ELISA Enzyme-linked Immunosorbent Assay
FHR Fetal Heart Rate
HCA Hierarchical Clustering Analysis
ITML Information-Theoretic Metric Learning
KITML Kernelized Information-Theoretic Metric Learning
KNN k-Nearest Neighbor
LMNN Large Margin Nearest Neighbors
mAbs Monoclonal Antibodies
PCA Principal Component Analysis
QSAR Quantitative Structure Activity Relationship
RBF Radial Basis Function
SE-DML Severity Estimation using Distance Metric Learning
SVM Support Vector Machine
TCGA The Cancer Genome Atlas
UC Uterine Contraction
UCI University of California-Irvine
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Appendix B. List of Symbols
Symbol Definition
A learned positive semi-definite m by m parameter matrix in a Mahalanobis dis-
tance metric
A0 prior positive semi-definitem bym parameter matrix in a Mahalanobis distance
metric
β projection parameter (Lagrange multiplier) corresponding to the current con-
straint
C number of classes in a data set
D inequivalent constraint set
d(x,y) distance between x and y
d(A0||A) distance between Pr(x|A) and Pr(x|A0)
ei unit basis vectors in which only the entry i is 1 and the rest are 0
E+ positive control
E− negative control
E?i group i with unknown severity level
γ kernel parameter in radial basis function kernel
FN number of false negatives
FP number of false positives
K learned positive semi-definite n by n kernel matrix in a distance metric
K0 prior positive semi-definite n by n kernel matrix in a distance metric
l lower bound of the constraints
m number of features in a sample
n number of samples in a data set
Pmacro precision in macro-averaged F1
Rmacro recall in macro-averaged F1
Pr(x|A) multivariate Gaussian distribution where A−1 is the covariance matrix
Σ Covariance Matrix
si silhouette coefficient for ith sample
S equivalent constraint set
TN number of true negatives
TP number of true positives
u upper bound of the constraints
W test statistic in Wilcoxon signed-ranks test
X a set of data points
yi severity level for group i
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Appendix C. 10-Fold Cross Validation for Decision Tree Classification
A 10-fold cross validation [118] was used here to estimate the DTC models clas-
sification accuracy on new data with unknown class labels. This method consists of
splitting known data into 10 equal parts, about 90% of the data were used to train
the algorithm and the classification accuracy was tested with the remaining 10% of
the data (cross validation). This process was repeated 10 times using different parts
of the data for training and cross validation. The classification accuracy estimate was
defined as the average classification accuracy for the 10 iterations. The classification
accuracy estimate of our DTC model built using training data set 1 was 98.1%; the
corresponding Confusion Matrix is shown in Table C.1. For training data set 2, the
average classification accuracy for the DTC model was 96.2%. The Confusion Matrix
is shown in Table C.2.
Table C.1: Confusion Matrix of DTC model in Figure 5.6(a) for 10-fold cross valida-
tion
Classifier Outcome Test accuracy (98.1%)
Safe CD28
Known Safe 132 4 False alarm/False positive 2.9%
CD28 0 80 Misdetection/False negative 0%
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Table C.2: Confusion Matrix of DTC model in Figure 5.7(a) for 10-fold cross valida-
tion
Classifier Outcome Test accuracy (96.2%)
Safe CD28
Known Safe 179 5 False alarm/False positive 2.7%
CD28 5 75 Misdetection/False negative 6.25%
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Appendix D. Sample Size Requirement Assessment for Binary Severity
Estimation
In order to perform clustering (by PCA followed by K-means clustering) or clas-
sification (by DTC), we need to estimate sample size. There exist several approaches
that could be used to perform this estimation, depending on the data set and focus of
study [75, 119, 120, 121]. We present in this appendix several approaches that proved
useful for our datasets.
D.1 PCA Followed by K-means Clustering
First we estimate sample size for PCA followed by K-means clustering. We select
80 samples at random from each of the negative control sets (PBS and AutoPlasma)
and the Anti-CD28 SA set for a total of 240 samples. This subset of data was used
to estimate sample size.
Before we estimate sample size for unlabeled data, it is instructive to use labeled
sets for reference. In our case we had a labeled set of PBS, AutoPlasma and Anti-
CD28 SA. We performed PCA followed by K-means clustering, specifying 3 clusters.
First we used only 6 samples from the dataset, and applied PCA followed by K-
means clustering 10 times. We then computed the average error rate by comparing
the clustering results to the labels of the data. Next, we included three more samples
(selected at random) in the dataset and applied the algorithm again. We repeated
this procedure until we reached all 240 samples available for analysis. The results are
illustrated in Figure D.1(a). It shows that the error rates stabilized after about 100
samples, indicating that this is approximately the lower bound on sample size.
When labels are not available, we can generate artificial data with the same dis-
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tribution as the data we need to process, and employ a similar process. In our case,
we generated three groups of artificial data using the statistics from the samples of
PBS, AutoPlasma and Anti-CD28 SA. We generated 240 samples of artificial data in
total. The sample size estimation was performed through the same procedure as with
assay data, and the results of this assessment are illustrated in Figure D.1(b). Here
the error rates seem to stabilize after about 80 samples, a result sufficiently close to
the values found with the real data (which was 100). The use of artificial data would
probably require the use of a guard band, adopting a somewhat higher sample size in
practice than the one that was estimated in simulations.
Figure D.1: Percentage error as function of the number of samples used: (a) Measured
data; (b) Artificially generated data
When the labels for the handled data are unknown, there are several other valid
approaches. As an example, we used the silhouette metric [75] to estimate the ad-
equate number of samples necessary to get consistent results with PCA followed by
K-means clustering. The silhouette metric provides an assessment of how good the
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clustering results are, irrespective of the clustering method. It measures how close
data samples are placed together within defined clusters, and how far away the clus-
ters are from each other. This metric is commonly used to assess the optimal number
of clusters k in K-means clustering [75]. The value provided by the silhouette metric
is calculated for different values of k (i.e. k = 2, 3, 4, . . . , 9), and the value of k that
maximizes the metric is chosen.
We used the silhouette metric to obtain optimal values of k for different sample
sizes out of our 240-sample set. We started by choosing 12 samples at random to
develop the estimate. We repeated the estimation by increasing the sample set by 12
samples at a time, until all 240 samples were included. The process was repeated 10
times. The average optimal values for k for each sample size are plotted in Figure D.2.
The number of clusters stabilized at k = 3 after 120 samples. The approach could be
used for other data sets in a similar manner.
D.2 Decision Tree Classification
We applied DTC on a training data set with samples from the ”CD28” class and
samples from the AutoPlasma and PBS classes. We started with five (5) samples
in each class, and increased the sample set of each class by 1 sample each time,
till there were 80 samples in each class. We built the DTC model for each sample
set. The accuracy of the models is shown in Figure D.3(a). We observed that the
accuracy levels were inconsistent for small sample sizes. The accuracy level stabilized
for sample sizes that exceed 20. Moreover, when the sample size of each class was
below 20, the root nodes of the DTC models appeared to be picked randomly from
all 11 cytokines. When the sample size of each class was above 20, almost all the root
nodes of the DTC models were IFN-γ.
Next we performed the process of estimating sample size by using synthetic data.
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Figure D.2: Optimal number of clusters for different sample sizes, based on the
silhouette metric
Synthetic data were generated based on the statistics of two classes: CD28 class (class
1) and samples from PBS and AutoPlasma (class 2). DTC was applied on these two
classes. The accuracies for different sample sizes are shown in Figure D.3(b). The
accuracy stabilizes after 50-60 samples. Since we have two classes, the total number
of required samples is 100 -120.
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Figure D.3: Optimal number of clusters for different sample sizes, based on the
silhouette metric
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